1 | B (migalastat) | 1件: Migalastat Migalastat | 1件: D10359
D10359
| - | - | 1件: 19 19 |
2 | B / Phuket / 3073/2013-like virus) | - | - | - | - | 1件: 53 53 |
3 | B-CIT and SPECT imaging | - | - | - | - | 1件: 6 6 |
4 | B-lines SE | - | - | - | - | 3件: 58 58, 86, 215 |
5 | B-Lymphocyte Stimulator (BLyS) | - | - | - | - | 1件: 65 65 |
6 | B-peptide-CRM197 conjugate | 1件: Corynebacterium diphtheriae CRM197 protein Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 |
7 | B-STN DBS | - | - | - | - | 1件: 6 6 |
8 | B. lactis B94 | - | - | - | - | 1件: 193 193 |
9 | B. theta | - | - | - | - | 1件: 96 96 |
10 | B001 injection | - | - | - | - | 1件: 13 13 |
11 | B03BB01 | - | - | - | - | 1件: 46 46 |
12 | B2-ASmedic | - | - | - | - | 1件: 97 97 |
13 | B6, B12, L-methylfolate | 1件: Levomefolic acid Levomefolic acid | 1件: D09353
D09353
| - | - | 1件: 6 6 |
14 | B: 2 dosis | - | - | - | - | 1件: 97 97 |
15 | Bacille Calmette-Guerin vaccine | - | - | - | - | 1件: 13 13 |
16 | Bacille of Calmette-Guerin | - | - | - | - | 1件: 13 13 |
17 | Background Treatment | - | - | - | - | 1件: 46 46 |
18 | Baclofen | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 7件: 2 2, 10, 13, 18, 65, 149, 206 |
19 | Baclofen 20 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
20 | Baclofen ER Capsules (GRS) 10 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
21 | Baclofen ER Capsules (GRS) 20 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
22 | Baclofen ER Capsules (GRS) 30mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
23 | Baclofen ER Capsules (GRS) 40mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
24 | Baclofen ER Capsules (GRS) 50 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
25 | Baclofen IR | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
26 | Baclofen Tablets USP | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
27 | Baclofen Tablets USP 10 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
28 | BACLOFENE | - | - | - | - | 1件: 10 10 |
29 | Bacteriophage | - | - | - | - | 1件: 65 65 |
30 | Bacteriophage preparation | - | - | - | - | 1件: 96 96 |
31 | Bacteriotherapy | - | - | - | - | 2件: 96 96, 97 |
32 | Bactrim | 1件: Trimethoprim Trimethoprim | 2件: D00145
D00145
,
D06236
| - | - | 1件: 299 299 |
33 | BAF312 | - | - | - | - | 2件: 13 13, 50 |
34 | BAF312 0,25 mg tablet | - | - | - | - | 1件: 13 13 |
35 | BAF312 0,5 mg tablet | - | - | - | - | 1件: 50 50 |
36 | BAF312 0.25 mg | - | - | - | - | 1件: 50 50 |
37 | BAF312 0.25 mg tablet | - | - | - | - | 1件: 50 50 |
38 | BAF312 0.25mg tablet | - | - | - | - | 1件: 50 50 |
39 | BAF312 0.5 mg | - | - | - | - | 1件: 50 50 |
40 | BAF312 0.50 mg | - | - | - | - | 1件: 50 50 |
41 | BAF312 1 mg | - | - | - | - | 1件: 50 50 |
42 | BAF312 1 mg tablet | - | - | - | - | 2件: 13 13, 50 |
43 | BAF312 1mg | - | - | - | - | 1件: 50 50 |
44 | BAF312 1mg tablet | - | - | - | - | 1件: 50 50 |
45 | BAF312 2 mg | - | - | - | - | 1件: 50 50 |
46 | BAF312 2 mg tablet | - | - | - | - | 1件: 50 50 |
47 | BAF312 2mg | - | - | - | - | 1件: 50 50 |
48 | BAF312 4 mg tablet | - | - | - | - | 1件: 13 13 |
49 | BAF312 4mg tablet | - | - | - | - | 1件: 50 50 |
50 | BAF312 5 mg tablet | - | - | - | - | 1件: 50 50 |
51 | BAF312 hemifumarate | - | - | - | - | 2件: 13 13, 50 |
52 | BAF312A | - | - | - | - | 1件: 13 13 |
53 | BAF312X | - | - | - | - | 1件: 50 50 |
54 | Bafiertam | 1件: Monomethyl fumarate Monomethyl fumarate | 1件: D11492
D11492
| - | - | 1件: 13 13 |
55 | BAL | - | - | - | - | 5件: 49 49, 51, 84, 85, 299 |
56 | Balance | 1件: Isoxaflutole Isoxaflutole | - | - | - | 8件: 6 6, 11, 13, 81, 113, 122, 149, 299 |
57 | Balance platform therapy | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
58 | Balance Training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
59 | Balance Training with Nintendo Wii Fit | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
60 | Ballon Pulmonary Angioplasty | - | - | - | - | 1件: 88 88 |
61 | Balloon Pulmonary Angioplasty (BPA) | - | - | - | - | 1件: 88 88 |
62 | Balsalazide | 1件: Balsalazide Balsalazide | 2件: D02715
D02715
,
D07488
| - | - | 1件: 97 97 |
63 | Balsalazide Disodium | 1件: Balsalazide Balsalazide | 2件: D02715
D02715
,
D07488
| - | - | 1件: 97 97 |
64 | Baminercept | 1件: Baminercept Baminercept | 1件: D08866
D08866
| 1件: LTB LTB 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 4件: 13 13, 46, 53, 97 |
65 | Baminercept alfa | 1件: Baminercept Baminercept | 1件: D08866
D08866
| 1件: LTB LTB 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 |
66 | Baminercept alfa (BG9924) | 1件: Baminercept Baminercept | 1件: D08866
D08866
| 1件: LTB LTB 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 |
67 | Band | - | - | - | - | 2件: 6 6, 97 |
68 | Bardoxolone | 1件: Bardoxolone Bardoxolone | 1件: D09584
D09584
| - | - | 7件: 66 66, 67, 84, 85, 86, 218, 222 |
69 | Bardoxolone methyl | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 7件: 66 66, 67, 84, 85, 86, 218, 222 |
70 | Bardoxolone methyl 10 mg | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 1件: 67 67 |
71 | Bardoxolone methyl 15 mg | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 1件: 67 67 |
72 | Bardoxolone methyl 20 mg | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 1件: 67 67 |
73 | Bardoxolone methyl 5 mg | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 1件: 67 67 |
74 | Bardoxolone methyl capsules | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 4件: 66 66, 67, 86, 222 |
75 | Bardoxolone methyl oral capsule | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 1件: 67 67 |
76 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 1件: 86 86 |
77 | Bardoxolone Metile | 1件: Bardoxolone Bardoxolone | 1件: D09584
D09584
| - | - | 1件: 67 67 |
78 | Baricinitib | - | - | - | - | 1件: 49 49 |
79 | Baricitinib | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 13件: 41 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 |
80 | Baricitinib 2 MG | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 53 53 |
81 | Baricitinib 2 MG [Olumiant] | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 162 162 |
82 | Baricitinib Oral Tablet [Olumiant] | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
83 | Baricitinib treatment | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
84 | Baricitinib, olumiant® | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
85 | Barium | 1件: Barium Barium | - | - | - | 3件: 2 2, 19, 98 |
86 | BARNASCAN | - | - | - | - | 1件: 88 88 |
87 | Bascial prescription plus or minus herbs depend on symptoms | - | - | - | - | 1件: 97 97 |
88 | Baseline disease modifying therapies (DMTs) | - | - | - | - | 1件: 13 13 |
89 | Baseline Treatment | - | - | - | - | 1件: 13 13 |
90 | Basiliximab | 1件: Basiliximab Basiliximab | 1件: D03058
D03058
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 5件: 2 2, 50, 97, 222, 228 |
91 | Basimglurant | 1件: Basimglurant Basimglurant | 1件: D10864
D10864
| - | - | 1件: 158 158 |
92 | BASSADO | - | - | - | - | 1件: 23 23 |
93 | BASSADO 10CPS 100MG | - | - | - | - | 1件: 23 23 |
94 | BAT1406 | - | - | - | - | 1件: 271 271 |
95 | BAT1806 | - | - | - | - | 1件: 46 46 |
96 | BAT1806 injection | - | - | - | - | 1件: 46 46 |
97 | BAT4406F | - | - | - | - | 1件: 13 13 |
98 | Bavisant | 1件: Bavisant Bavisant | 1件: D09870
D09870
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
99 | Bavisant dihydrochloride monohydrate | 1件: Bavisant Bavisant | 1件: D09870
D09870
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
100 | BAVISANT HYDROCHLORIDE MONOHYDRATE | 1件: Bavisant Bavisant | 1件: D09870
D09870
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
101 | Bawei Shenqi Pill | - | - | - | - | 1件: 271 271 |
102 | BAX 111 | - | - | - | - | 1件: 288 288 |
103 | BAX111 | - | - | - | - | 1件: 288 288 |
104 | BAX930 | - | - | - | - | 1件: 64 64 |
105 | BAX930 - RECOMBINANT HUMAN ADAMTS13 | - | - | - | - | 1件: 64 64 |
106 | BAX930 or SHP655 | - | - | - | - | 1件: 64 64 |
107 | BAY 59-7939 | - | - | - | - | 1件: 210 210 |
108 | BAY 63-2521 | - | - | - | - | 2件: 86 86, 88 |
109 | BAY 63-2521 0.06 % | - | - | - | - | 1件: 86 86 |
110 | BAY 63-2521 0.3 % | - | - | - | - | 1件: 86 86 |
111 | BAY 63-2521 coated tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 |
112 | BAY 63-2521 coated tablets 1 mg | - | - | - | - | 2件: 86 86, 88 |
113 | BAY 63-2521 coated tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 |
114 | BAY 63-2521 coated tablets 2 mg | - | - | - | - | 2件: 86 86, 88 |
115 | BAY 63-2521 coated tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 |
116 | BAY 63-2521 IR coated tablet 1.0 mg | - | - | - | - | 1件: 88 88 |
117 | BAY 63-2521 IR coated tablet 1.5 mg | - | - | - | - | 1件: 88 88 |
118 | BAY 63-2521 IR coated tablet 2.0 mg | - | - | - | - | 1件: 88 88 |
119 | BAY 63-2521 IR coated tablet 2.5 mg | - | - | - | - | 1件: 88 88 |
120 | BAY 63-2521 IR tablet 0.5 mg | - | - | - | - | 1件: 88 88 |
121 | BAY 63-2521 IR tablet 1.0 mg | - | - | - | - | 1件: 88 88 |
122 | BAY 63-2521 IR tablet 1.5 mg | - | - | - | - | 1件: 88 88 |
123 | BAY 63-2521 IR tablet 2.0 mg | - | - | - | - | 1件: 88 88 |
124 | BAY 63-2521 IR tablet 2.5 mg | - | - | - | - | 1件: 88 88 |
125 | BAY 63-2521 IR tablets 0.5 mg | - | - | - | - | 1件: 86 86 |
126 | BAY 63-2521 IR tablets 1 mg | - | - | - | - | 1件: 86 86 |
127 | BAY 63-2521 IR tablets 1.0 mg | - | - | - | - | 1件: 86 86 |
128 | BAY 63-2521 IR tablets 1.5 mg | - | - | - | - | 1件: 86 86 |
129 | BAY 63-2521 IR tablets 2.0 mg | - | - | - | - | 1件: 86 86 |
130 | BAY 63-2521 IR tablets 2.5 mg | - | - | - | - | 1件: 86 86 |
131 | BAY 63-2521 Tablet | - | - | - | - | 1件: 86 86 |
132 | BAY 63-2521 tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 |
133 | BAY 63-2521 tablets 1 mg | - | - | - | - | 2件: 86 86, 88 |
134 | BAY 63-2521 tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 |
135 | BAY 63-2521 tablets 2 mg | - | - | - | - | 2件: 86 86, 88 |
136 | BAY 63-2521 tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 |
137 | BAY 79-4998 | - | - | - | - | 1件: 13 13 |
138 | BAY 85-8501 | - | - | - | - | 1件: 299 299 |
139 | BAY q 3939 | - | - | - | - | 1件: 299 299 |
140 | Bay Q 6256 | - | - | - | - | 1件: 86 86 |
141 | BAY1237592 | - | - | - | - | 2件: 86 86, 88 |
142 | BAY63-2521 | - | - | - | - | 3件: 51 51, 86, 299 |
143 | BAY85-8501 | - | - | - | - | 1件: 299 299 |
144 | BAY86-5046 | - | - | - | - | 1件: 13 13 |
145 | BAY86-5046_Interferon-beta-1b | - | - | - | - | 1件: 13 13 |
146 | BAYQ3939 | - | - | - | - | 1件: 299 299 |
147 | Bazedoxifene | 1件: Bazedoxifene Bazedoxifene | - | - | - | 1件: 13 13 |
148 | Bazedoxifene Acetate | 2件: Acetate Acetate, Bazedoxifene | - | - | - | 1件: 13 13 |
149 | BBP-418 | - | - | - | - | 1件: 113 113 |
150 | BBP-671 | - | - | - | - | 2件: 245 245, 246 |
151 | BBR 2778 | - | - | - | - | 2件: 11 11, 13 |
152 | BBT-401-1S | - | - | - | - | 1件: 97 97 |
153 | BBT-401-1S, Multiple doses | - | - | - | - | 1件: 97 97 |
154 | BBT-401-1S, Single dose | - | - | - | - | 1件: 97 97 |
155 | BBT-877, Multiple doses | - | - | - | - | 1件: 85 85 |
156 | BBT-877, Single dose | - | - | - | - | 1件: 85 85 |
157 | BCD-033 (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
158 | BCD-054 180 mcg | - | - | - | - | 1件: 13 13 |
159 | BCD-054 240 mcg | - | - | - | - | 1件: 13 13 |
160 | BCD-055 | - | - | - | - | 2件: 46 46, 271 |
161 | BCD-063 | - | - | - | - | 1件: 13 13 |
162 | BCD-085 | - | - | - | - | 2件: 93 93, 271 |
163 | BCD-089 | - | - | - | - | 1件: 46 46 |
164 | BCD-089, 162 mg, s/c, q2w | - | - | - | - | 1件: 46 46 |
165 | BCD-089, 162 mg, s/c, qw | - | - | - | - | 1件: 46 46 |
166 | BCD-132 | - | - | - | - | 1件: 13 13 |
167 | BCD-132, 125 mg | - | - | - | - | 1件: 13 13 |
168 | BCD-132, 500 mg | - | - | - | - | 1件: 13 13 |
169 | BCD-148 | - | - | - | - | 1件: 62 62 |
170 | BCG | - | - | - | - | 1件: 299 299 |
171 | BCG TICE Vaccine | - | - | - | - | 1件: 299 299 |
172 | BCG20-0134 | - | - | - | - | 1件: 13 13 |
173 | BCX9930 | - | - | - | - | 3件: 62 62, 66, 222 |
174 | BCX9930 hydrochloride | - | - | - | - | 3件: 62 62, 66, 222 |
175 | BCX9930 monotherapy | - | - | - | - | 1件: 62 62 |
176 | BD | - | - | - | - | 2件: 28 28, 46 |
177 | BDMARD | - | - | - | - | 1件: 46 46 |
178 | BDMARD treatment | - | - | - | - | 1件: 271 271 |
179 | BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept) | 5件: Abatacept Abatacept, Adalimumab, Etanercept, Golimumab, Infliximab | 5件: D00742
D00742
,
D02597
,
D02598
,
D03203
,
D04358
| 4件: CD80 CD80, CD86, LTA, TNF 💬 | 73件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
180 | Beam | 1件: Tricyclazole Tricyclazole | - | - | - | 2件: 6 6, 51 |
181 | BEAM Regimen | - | - | - | - | 1件: 13 13 |
182 | Bean | 1件: Bean Bean | - | - | - | 1件: 96 96 |
183 | Beclometasone | - | - | - | - | 1件: 97 97 |
184 | Beclometasone dipropionate | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 2件: D00689
D00689
,
D07495
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 85 85, 97 |
185 | Beclomethasone dipropionate | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 2件: D00689
D00689
,
D07495
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 97 97, 98 |
186 | Beclomethasone diproprionate | - | - | - | - | 1件: 97 97 |
187 | Bee venom | - | - | - | - | 1件: 6 6 |
188 | Bee venom pharmacopuncture | - | - | - | - | 1件: 70 70 |
189 | Beetainterferoni -1a | - | - | - | - | 1件: 13 13 |
190 | Beetroot juice | - | - | - | - | 1件: 86 86 |
191 | BEFIRADOL | - | - | - | - | 1件: 6 6 |
192 | Befizal | - | - | - | - | 1件: 94 94 |
193 | BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée | - | - | - | - | 1件: 94 94 |
194 | Begelomab | 1件: Begelomab Begelomab | - | - | - | 1件: 50 50 |
195 | Behavior and neuropsychometric evaluations | - | - | - | - | 1件: 78 78 |
196 | Behavioral: 50 patients will have a Free Choice between Filgotinib and anti TNF | 1件: Filgotinib Filgotinib | 1件: D10871
D10871
| 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
197 | Behavioral: 6 months weight resistance and balance program | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
198 | Behavioral: 60-minutes of steady state exercise | - | - | - | - | 1件: 265 265 |
199 | Behavioral: AbbVie Care 2.0 | - | - | - | - | 4件: 46 46, 96, 97, 271 |
200 | Behavioral: Adherence counseling | - | - | - | - | 1件: 13 13 |
201 | Behavioral: Administration of probiotic (L. rhamnosus and L. acidophilus) | 1件: Lactobacillus acidophilus Lactobacillus acidophilus | 1件: D04349
D04349
| - | - | 1件: 97 97 |
202 | Behavioral: Aerobic exercise | - | - | - | - | 1件: 299 299 |
203 | Behavioral: anal dilation | - | - | - | - | 1件: 291 291 |
204 | Behavioral: AO+VR | - | - | - | - | 1件: 149 149 |
205 | Behavioral: Assessment of cognition | - | - | - | - | 1件: 6 6 |
206 | Behavioral: Assessment of depression | - | - | - | - | 1件: 6 6 |
207 | Behavioral: Assessment of disability | - | - | - | - | 1件: 13 13 |
208 | Behavioral: Assessment of impact of MS on cognition | - | - | - | - | 1件: 13 13 |
209 | Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors | - | - | - | - | 1件: 6 6 |
210 | Behavioral: Assessment of quality of life | - | - | - | - | 1件: 6 6 |
211 | Behavioral: Assessment of severity of ICD (impulse control disorders) | - | - | - | - | 1件: 6 6 |
212 | Behavioral: Assessment of severity of Parkinson Disease | - | - | - | - | 1件: 6 6 |
213 | Behavioral: Attention Control | - | - | - | - | 1件: 6 6 |
214 | Behavioral: Augmented Reality Multi-Modal Training | - | - | - | - | 1件: 6 6 |
215 | Behavioral: B-HIPE (Brief High Impact Preparatory Experience) | - | - | - | - | 1件: 13 13 |
216 | Behavioral: Balance & Strengthening Exercises | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
217 | Behavioral: Balance exercise | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 299 299 |
218 | Behavioral: Balance Training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 2件: 6 6, 13 |
219 | Behavioral: BCI-FIT active querying | - | - | - | - | 3件: 2 2, 6, 17 |
220 | Behavioral: BCI-FIT adaptive signal modeling | - | - | - | - | 3件: 2 2, 6, 17 |
221 | Behavioral: BCI-FIT language modeling | - | - | - | - | 3件: 2 2, 6, 17 |
222 | Behavioral: BCI-FIT multi-modal access | - | - | - | - | 3件: 2 2, 6, 17 |
223 | Behavioral: Brisk walking and balance training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
224 | Behavioral: Building Better Caregivers Workshop | - | - | - | - | 1件: 6 6 |
225 | Behavioral: Cannabis questionnaire | 1件: Medical Cannabis Medical Cannabis | - | - | - | 2件: 46 46, 271 |
226 | Behavioral: CBT and sleep hygiene | - | - | - | - | 1件: 6 6 |
227 | Behavioral: CHDR Monitoring Remotely (MORE) | - | - | - | - | 1件: 113 113 |
228 | Behavioral: Clinical characteristics of AMS patients | - | - | - | - | 1件: 17 17 |
229 | Behavioral: CO+VR | - | - | - | - | 1件: 149 149 |
230 | Behavioral: CO-OP treatment protocol | - | - | - | - | 1件: 6 6 |
231 | Behavioral: Cognitive and Behavioral experimental tasks | - | - | - | - | 2件: 6 6, 127 |
232 | Behavioral: Collaborative Care (CC) | - | - | - | - | 1件: 13 13 |
233 | Behavioral: colonic lavage | - | - | - | - | 1件: 291 291 |
234 | Behavioral: Combined balance and brisk walking training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
235 | Behavioral: Conservative Measures for Orthostatic Hypotension | - | - | - | - | 2件: 6 6, 17 |
236 | Behavioral: conservative treatment | - | - | - | - | 1件: 291 291 |
237 | Behavioral: Control Group Typically Developing | - | - | - | - | 1件: 113 113 |
238 | Behavioral: Dexterity | - | - | - | - | 1件: 6 6 |
239 | Behavioral: Diet | - | - | - | - | 1件: 265 265 |
240 | Behavioral: Diet and water adjustment | 1件: Water Water | 1件: D00001
D00001
| - | - | 1件: 67 67 |
241 | Behavioral: Diet Counseling | - | - | - | - | 1件: 96 96 |
242 | Behavioral: Dietary Counseling | - | - | - | - | 1件: 46 46 |
243 | Behavioral: Dietary guidance | - | - | - | - | 1件: 46 46 |
244 | Behavioral: Dietary Guidelines for Americans Diet | - | - | - | - | 1件: 13 13 |
245 | Behavioral: Dietary recommendations | - | - | - | - | 1件: 46 46 |
246 | Behavioral: Dual Task | - | - | - | - | 1件: 6 6 |
247 | Behavioral: Duchenne Muscular Dystrophy group with Deflazacort | 1件: Deflazacort Deflazacort | 1件: D03671
D03671
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
248 | Behavioral: Duchenne Muscular Dystrophy group with Prednisone/Predisolone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
249 | Behavioral: Duchenne Muscular Dystrophy group without Corticosteroids therapy | - | - | - | - | 1件: 113 113 |
250 | Behavioral: Dyadic Psychological Support (DPS) | - | - | - | - | 1件: 96 96 |
251 | Behavioral: ECOCAPTURE | - | - | - | - | 2件: 6 6, 127 |
252 | Behavioral: Emotion Assessment | - | - | - | - | 1件: 6 6 |
253 | Behavioral: Environmental Decontamination | - | - | - | - | 1件: 299 299 |
254 | Behavioral: Exercise | - | - | - | - | 3件: 6 6, 265, 299 |
255 | Behavioral: Exercise only | - | - | - | - | 1件: 6 6 |
256 | Behavioral: Exercise Training | - | - | - | - | 1件: 265 265 |
257 | Behavioral: exercise+multi-modal sensory feedback (MMSF) | - | - | - | - | 1件: 6 6 |
258 | Behavioral: Flexibility and postural exercise | - | - | - | - | 1件: 299 299 |
259 | Behavioral: Flexibility and strengthening exercise | - | - | - | - | 1件: 6 6 |
260 | Behavioral: Gait and balance | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
261 | Behavioral: gait and balance training program | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
262 | Behavioral: General healthy eating | - | - | - | - | 1件: 271 271 |
263 | Behavioral: Healthy age-matched controls | - | - | - | - | 1件: 6 6 |
264 | Behavioral: heart health educational program | - | - | - | - | 1件: 49 49 |
265 | Behavioral: High/Low Sitosterol | 1件: beta-Sitosterol beta-Sitosterol | 1件: D08518
D08518
| - | - | 1件: 260 260 |
266 | Behavioral: Hypnosis | - | - | - | - | 1件: 96 96 |
267 | Behavioral: ICM_APATHY_TASKS | - | - | - | - | 2件: 6 6, 127 |
268 | Behavioral: Impact of four week coaching program on dietary habits | - | - | - | - | 1件: 13 13 |
269 | Behavioral: In-home Exercise Training | - | - | - | - | 1件: 113 113 |
270 | Behavioral: Increased dietary intake of salmon or cod | 1件: Salmon, unspecified Salmon, unspecified | - | - | - | 1件: 97 97 |
271 | Behavioral: learning | - | - | - | - | 1件: 13 13 |
272 | Behavioral: Levodopa or acupuncture | 1件: Levodopa Levodopa | 1件: D00059
D00059
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
273 | Behavioral: Lifestyle | - | - | - | - | 1件: 58 58 |
274 | Behavioral: Low Starch Diet (LSD) | - | - | - | - | 1件: 271 271 |
275 | Behavioral: Low-Impact Exercise Control | - | - | - | - | 1件: 6 6 |
276 | Behavioral: Medical Marijuana | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
277 | Behavioral: meditation | - | - | - | - | 1件: 13 13 |
278 | Behavioral: Memory | - | - | - | - | 1件: 6 6 |
279 | Behavioral: Modified Paleolithic Elimination diet | - | - | - | - | 1件: 13 13 |
280 | Behavioral: MOntreal Cognitive Assessment (MoCA) | - | - | - | - | 1件: 17 17 |
281 | Behavioral: Motivational Interviewing | - | - | - | - | 1件: 13 13 |
282 | Behavioral: Neuro-psychological Assessment | - | - | - | - | 1件: 240 240 |
283 | Behavioral: Neurocognitive testing | - | - | - | - | 1件: 19 19 |
284 | Behavioral: OM Meditation | - | - | - | - | 1件: 6 6 |
285 | Behavioral: Other Academic sham tutoring | - | - | - | - | 1件: 34 34 |
286 | Behavioral: Participant open-response writing | - | - | - | - | 1件: 6 6 |
287 | Behavioral: Participant self-assessment surveys | - | - | - | - | 1件: 6 6 |
288 | Behavioral: PAT sessions | - | - | - | - | 1件: 6 6 |
289 | Behavioral: Pelvic floor muscle exercise-based behavioral therapy | - | - | - | - | 1件: 6 6 |
290 | Behavioral: phenylalanine restricted diet | 1件: Phenylalanine Phenylalanine | 1件: D00021
D00021
| - | - | 1件: 240 240 |
291 | Behavioral: Phonation | - | - | - | - | 1件: 6 6 |
292 | Behavioral: Physical Activity Together for PwMS and their CGs (PAT-MS) | - | - | - | - | 1件: 13 13 |
293 | Behavioral: physical exam and UPDRS part III assessment | - | - | - | - | 1件: 6 6 |
294 | Behavioral: Physical Therapy | - | - | - | - | 1件: 6 6 |
295 | Behavioral: PICC line placement | - | - | - | - | 1件: 19 19 |
296 | Behavioral: pre DBS patients responding to the DBS-PS scale | - | - | - | - | 1件: 6 6 |
297 | Behavioral: Protein and calorie controlled diet | - | - | - | - | 1件: 251 251 |
298 | Behavioral: quality of life assessment | - | - | - | - | 1件: 81 81 |
299 | Behavioral: Questionnaire | - | - | - | - | 1件: 46 46 |
300 | Behavioral: Questionnaires | - | - | - | - | 2件: 28 28, 49 |
301 | Behavioral: reading tutoring intervention | - | - | - | - | 1件: 34 34 |
302 | Behavioral: Regular exercise | - | - | - | - | 1件: 113 113 |
303 | Behavioral: Resistance exercise | - | - | - | - | 1件: 299 299 |
304 | Behavioral: Resistance Training | - | - | - | - | 1件: 6 6 |
305 | Behavioral: respiratory and exercise therapy | - | - | - | - | 1件: 88 88 |
306 | Behavioral: respiratory and exercise therapy with supplemental oxygen | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 1件: 88 88 |
307 | Behavioral: Rest | - | - | - | - | 1件: 6 6 |
308 | Behavioral: Restricted phenylalanine diet | 1件: Phenylalanine Phenylalanine | 1件: D00021
D00021
| - | - | 1件: 240 240 |
309 | Behavioral: Role of dopamine | 1件: Dopamine Dopamine | 2件: D00633
D00633
,
D07870
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
310 | Behavioral: self massage | - | - | - | - | 1件: 13 13 |
311 | Behavioral: Single Task | - | - | - | - | 1件: 6 6 |
312 | Behavioral: SIT Scoring | - | - | - | - | 1件: 2 2 |
313 | Behavioral: six-foods elimination diet | - | - | - | - | 1件: 98 98 |
314 | Behavioral: Sleep quality and physical activity | - | - | - | - | 1件: 13 13 |
315 | Behavioral: Smoking | - | - | - | - | 1件: 13 13 |
316 | Behavioral: smoking and alcohol assumption | 1件: Ethanol Ethanol | 4件: D00068
D00068
,
D02798
,
D04855
,
D06542
| - | - | 1件: 298 298 |
317 | Behavioral: Speech Intelligibility Test (SIT) | - | - | - | - | 1件: 2 2 |
318 | Behavioral: Step Tracking | - | - | - | - | 1件: 13 13 |
319 | Behavioral: steps per day | - | - | - | - | 1件: 6 6 |
320 | Behavioral: Strength training | - | - | - | - | 1件: 6 6 |
321 | Behavioral: stretching | - | - | - | - | 1件: 6 6 |
322 | Behavioral: Tai Chi | - | - | - | - | 1件: 6 6 |
323 | Behavioral: Telephone-based Cognitive Behavioral Therapy | - | - | - | - | 1件: 13 13 |
324 | Behavioral: The M.D. Anderson Symptom Inventory (MDASI) | - | - | - | - | 1件: 28 28 |
325 | Behavioral: Time Restricted Olive Oil Based (TROO) Ketogenic Diet | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: D03311
D03311
| - | - | 1件: 13 13 |
326 | Behavioral: TIP / IMPACT Plus Care Coordination | - | - | - | - | 3件: 46 46, 96, 97 |
327 | Behavioral: Tobacco Treatment Specialist (TTS) intervention | 1件: Tobacco leaf Tobacco leaf | - | - | - | 1件: 299 299 |
328 | Behavioral: Traditional Multi-Modal Training | - | - | - | - | 1件: 6 6 |
329 | Behavioral: Unsupervised exercise | - | - | - | - | 1件: 299 299 |
330 | Behavioral: Upper limb exercise | - | - | - | - | 1件: 6 6 |
331 | Behavioral: Water Tracking | 1件: Water Water | 1件: D00001
D00001
| - | - | 1件: 13 13 |
332 | Behavioral: Withings Blood Pressure Monitor | 1件: Methamidophos Methamidophos | - | - | - | 1件: 113 113 |
333 | Behavioral: Withings Body+ scale | - | - | - | - | 1件: 113 113 |
334 | Behavioral: Withings Steel HR | - | - | - | - | 1件: 113 113 |
335 | Belantamab mafodotin | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
336 | Belantamab mafodotin 1.9 mg/kg (8 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
337 | Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
338 | Belantamab mafodotin 2.5 mg/kg (4 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
339 | Belantamab mafodotin 2.5 mg/kg (6 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
340 | Belantamab mafodotin 2.5 mg/kg (8 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
341 | Belatacept | 1件: Belatacept Belatacept | 1件: D03222
D03222
| 2件: CD80 CD80, CD86 💬 | 12件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | 1件: 46 46 |
342 | Belcesiran | - | - | - | - | 1件: 231 231 |
343 | BELIMUMAB | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 12件: 11 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300 |
344 | Belimumab 1 mg/kg | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 46 46, 49 |
345 | Belimumab 10 mg | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 222 222 |
346 | Belimumab 10 mg/kg | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 3件: 43 43, 46, 49 |
347 | Belimumab 10 mg/kg plus standard therapy | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
348 | Belimumab 100 mg SC | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
349 | Belimumab 10mg/kg | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
350 | Belimumab 200 mg SC | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
351 | Belimumab 200 mg/mL | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
352 | Belimumab 4 mg/kg | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 46 46, 49 |
353 | Belimumab autoinjector | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
354 | Belimumab for IV | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
355 | Belimumab for SC | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
356 | Belimumab Injection | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
357 | Belimumab Injection [Benlysta] | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
358 | Belimumab or benlysta | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
359 | Belimumab plus Early Vaccination | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
360 | Belimumab plus Late Vaccination | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
361 | Beloranib | 1件: Beloranib Beloranib | - | - | - | 1件: 193 193 |
362 | Belumosudil | 1件: Belumosudil Belumosudil | 1件: D11815
D11815
| 1件: ROCK2 ROCK2 💬 | 21件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 |
363 | Belumosudil (KD025) | 1件: Belumosudil Belumosudil | 1件: D11815
D11815
| 1件: ROCK2 ROCK2 💬 | 21件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 |
364 | BEN-2001 | - | - | - | - | 1件: 6 6 |
365 | Benazepril | 1件: Benazepril Benazepril | 2件: D00620
D00620
,
D07499
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 4件: 49 49, 57, 218, 224 |
366 | Benazepril hydrochloride 10 milligram (mg) Tab | 1件: Benazepril Benazepril | 2件: D00620
D00620
,
D07499
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 218 218 |
367 | Benazepril Hydrochloride Tablets | 1件: Benazepril Benazepril | 2件: D00620
D00620
,
D07499
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 224 224 |
368 | Benazepril Pill | 1件: Benazepril Benazepril | 2件: D00620
D00620
,
D07499
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 49 49 |
369 | Benazepril, Valsartan and Fluvastatin | 3件: Benazepril Benazepril, Fluvastatin, Valsartan | 5件: D00400
D00400
,
D00620
,
D00892
,
D07499
,
D07983
| 3件: ACE ACE, AGTR1, HMGCR 💬 | 22件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Bile secretion, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Terpenoid backbone biosynthesis, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 218 218 |
370 | Bendamustine | 1件: Bendamustine Bendamustine | 1件: D07501
D07501
| - | - | 2件: 28 28, 61 |
371 | BENDAMUSTINE HYDROCHLORIDE | 1件: Bendamustine Bendamustine | 1件: D07501
D07501
| - | - | 1件: 61 61 |
372 | Bendamustine, Rituximab | 2件: Bendamustine Bendamustine, Rituximab | 2件: D02994
D02994
,
D07501
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 61 61 |
373 | BENDROFLUMETHIAZIDE | 1件: Bendroflumethiazide Bendroflumethiazide | 1件: D00650
D00650
| 1件: SLC12A3 SLC12A3 💬 | - | 1件: 67 67 |
374 | Benepali | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
375 | Benerva | - | - | - | - | 1件: 8 8 |
376 | Benlysta | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 5件: 43 43, 49, 53, 66, 222 |
377 | Benlysta (belimumab) | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 4件: 11 11, 49, 53, 222 |
378 | BENLYSTA - 120 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 120 MG 1 FLACONCINO | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 53 53 |
379 | Benlysta 400 mg powder for concentrate for solution for infusion | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 43 43, 49 |
380 | Benlysta 400 mg powder for concentrate for solution for infusions | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
381 | Benlysta 400mg polvere per concentrato per soluzione per infusione | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 43 43 |
382 | BENLYSTA? (belimumab) | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
383 | Benlysta® | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 49 49, 222 |
384 | BENLYSTA® (belimumab) | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 3件: 11 11, 66, 222 |
385 | BENLYSTA™ (belimumab) | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
386 | Benralizumab | 1件: Benralizumab Benralizumab | 1件: D09874
D09874
| 1件: IL5RA IL5RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 5件: 44 44, 45, 98, 162, 299 |
387 | BENSERAZIDE | 1件: Benserazide Benserazide | 1件: D03082
D03082
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
388 | BENSERAZIDE HYDROCHLORIDE | 1件: Benserazide Benserazide | 1件: D03082
D03082
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
389 | Benzbromaron | - | - | - | - | 1件: 86 86 |
390 | Benzbromaron AL | - | - | - | - | 1件: 86 86 |
391 | BENZBROMARONE | 1件: Benzbromarone Benzbromarone | 1件: D01056
D01056
| 1件: SLC22A12 SLC22A12 💬 | - | 1件: 86 86 |
392 | Benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 |
393 | Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 |
394 | Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 |
395 | Benznidazole | 1件: Benznidazole Benznidazole | 1件: D02489
D02489
| - | - | 1件: 65 65 |
396 | Benzofuran | 1件: Benzofuran Benzofuran | - | - | - | 1件: 6 6 |
397 | Benzoic acid | 1件: Benzoic acid Benzoic acid | 1件: D00038
D00038
| - | - | 1件: 51 51 |
398 | Benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala) | 2件: Alanine Alanine, Tyrosine | 2件: D00012
D00012
,
D00022
| - | - | 1件: 298 298 |
399 | Bepranemab | - | - | - | - | 1件: 5 5 |
400 | Berachin | - | - | - | - | 1件: 6 6 |
401 | Beraprost | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
402 | Beraprost Sodium | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
403 | Beraprost Sodium 314d Modified Release Tablets | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
404 | Beraprost Sodium Modified Release | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
405 | Berberine | 1件: Berberine Berberine | - | - | - | 2件: 97 97, 265 |
406 | Berberine Chloride | 2件: Berberine Berberine, Chloride ion | - | - | - | 1件: 97 97 |
407 | BERMEKIMAB | 1件: Bermekimab Bermekimab | 1件: D11253
D11253
| 1件: IL1A IL1A 💬 | 21件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Alzheimer disease, Cellular senescence, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Inflammatory bowel disease, Influenza A, Leishmaniasis, MAPK signaling pathway, Measles, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 51 51 |
408 | Bertilimumab | - | - | - | - | 2件: 97 97, 162 |
409 | Best Available Therapy (BAT) | - | - | - | - | 1件: 13 13 |
410 | Best Medical Treatment | - | - | - | - | 1件: 6 6 |
411 | Best médical treatment | - | - | - | - | 1件: 6 6 |
412 | Best Supportive Care (BSC) | - | - | - | - | 1件: 331 331 |
413 | Beta carotene | 1件: Beta carotene Beta carotene | 1件: D03101
D03101
| - | - | 1件: 96 96 |
414 | Beta carotene from Dunaliella algae | 1件: Beta carotene Beta carotene | 1件: D03101
D03101
| - | - | 1件: 96 96 |
415 | Beta Hydroxybutyrate | - | - | - | - | 1件: 2 2 |
416 | Beta-1,3/1,6-D-Glucan | - | - | - | - | 1件: 97 97 |
417 | Beta-1b interferoni | - | - | - | - | 1件: 13 13 |
418 | Beta-Adrenergic cocktail | - | - | - | - | 1件: 299 299 |
419 | Beta-Alanine | 2件: Alanine Alanine, beta-Alanine | 2件: D00012
D00012
,
D07561
| - | - | 1件: 13 13 |
420 | Beta-alanine supplementation | 2件: Alanine Alanine, beta-Alanine | 2件: D00012
D00012
,
D07561
| - | - | 1件: 13 13 |
421 | Beta-Carotene | 1件: Beta carotene Beta carotene | 1件: D03101
D03101
| - | - | 1件: 13 13 |
422 | Beta-cyclodextrin | 1件: Betadex Betadex | 1件: D02401
D02401
| - | - | 1件: 19 19 |
423 | Beta-Galactosidase | 1件: Tilactase Tilactase | 1件: D03348
D03348
| - | - | 1件: 19 19 |
424 | Beta-hydroxybuturate esters | - | - | - | - | 1件: 256 256 |
425 | Beta-Interferon | - | - | - | - | 1件: 13 13 |
426 | Beta-Mercaptoethylamine | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
427 | Beta-mercaptoethylamine Hydrochloride & 2-aminoethanethiol Hydrochloride | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
428 | BETACAROTENE | 1件: Beta carotene Beta carotene | 1件: D03101
D03101
| - | - | 1件: 13 13 |
429 | BETACONNECT | - | - | - | - | 1件: 13 13 |
430 | Betaconnect auto-injector | - | - | - | - | 1件: 13 13 |
431 | BETACONNECT auto-injector. | - | - | - | - | 1件: 13 13 |
432 | Betaconnect Autoinjector | - | - | - | - | 1件: 13 13 |
433 | BETACONNECT device | - | - | - | - | 1件: 13 13 |
434 | BETAFERON | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
435 | BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
436 | BETAFERON 250 mcg | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
437 | Betaferon 250 microgram/ml | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
438 | Betaferon 250 microgram/ml, powder and solvent for solution for injection | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
439 | Betaferon 250 microgram/mL, powder and solvent for solution for injection. | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
440 | Betaferon 250 microgramos | - | - | - | - | 1件: 13 13 |
441 | Betaferon 250mcg | - | - | - | - | 1件: 13 13 |
442 | Betaferon 250µg | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
443 | BETAFERON 500 mcg | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
444 | Betaferon 500 µg | - | - | - | - | 1件: 13 13 |
445 | Betaferon 500mcg | - | - | - | - | 1件: 13 13 |
446 | Betaferon 500µg | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
447 | BETAFERON SC 15F 0,25MG 15SIR | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
448 | BETAFERON*15CONFEZ 0,25MG/ML+ | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
449 | Betaferon, BAY86-5046 | - | - | - | - | 1件: 13 13 |
450 | Betaferon/Betaseron | - | - | - | - | 1件: 13 13 |
451 | Betaferon® | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
452 | BETAFERON® (interferon beta-1b) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
453 | Betaine | 1件: Betaine Betaine | 1件: D07523
D07523
| - | - | 2件: 201 201, 337 |
454 | Betaloc ZOK 100, 95 mg | - | - | - | - | 1件: 113 113 |
455 | Betaloc ZOK 25, 23,75 mg | - | - | - | - | 1件: 113 113 |
456 | Betamethasone | 1件: Betamethasone Betamethasone | 7件: D00244
D00244
,
D00972
,
D01357
,
D01402
,
D01637
,
D02032
,
D02286
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 7件: 2 2, 28, 46, 83, 90, 96, 235 |
457 | BETAMETHASONE ACIBUTATE | 1件: Betamethasone Betamethasone | 7件: D00244
D00244
,
D00972
,
D01357
,
D01402
,
D01637
,
D02032
,
D02286
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 |
458 | Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days | 3件: Acetate Acetate, Betamethasone, Phosphate ion | 7件: D00244
D00244
,
D00972
,
D01357
,
D01402
,
D01637
,
D02032
,
D02286
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 2 2 |
459 | Betaquik MCT supplement | - | - | - | - | 1件: 6 6 |
460 | Betaseron | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
461 | Betaseron (Interferon beta-1b, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
462 | Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
463 | Bethanechol | 1件: Bethanechol Bethanechol | 1件: D01000
D01000
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 98 98 |
464 | Bethkis | - | - | - | - | 1件: 299 299 |
465 | Better | - | - | - | - | 2件: 6 6, 13 |
466 | Bevacizumab | 1件: Bevacizumab Bevacizumab | 1件: D06409
D06409
| 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 9件: 13 13, 34, 85, 86, 87, 89, 227, 280, 331 |
467 | Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec) | 2件: Bevacizumab Bevacizumab, Imatinib | 3件: D01441
D01441
,
D06409
,
D08066
| 4件: ABL1 ABL1, KIT, PDGFRA, VEGFA 💬 | 45件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Acute myeloid leukemia, Axon guidance, Bladder cancer, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Glioma, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pancreatic cancer, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway, Viral myocarditis 💬 | 1件: 87 87 |
468 | Bevacizumab (Genitical Recombination) | 1件: Bevacizumab Bevacizumab | 1件: D06409
D06409
| 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 1件: 34 34 |
469 | BEVACIZUMAB ZIRCONIUM ZR-89 | 2件: Bevacizumab Bevacizumab, Bevacizumab zirconium Zr-89 | 1件: D06409
D06409
| 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 1件: 34 34 |
470 | Bevacuzimab spray | - | - | - | - | 1件: 227 227 |
471 | Bevantolol | 1件: Bevantolol Bevantolol | - | - | - | 1件: 8 8 |
472 | BEVANTOLOL HYDROCHLORIDE | 1件: Bevantolol Bevantolol | - | - | - | 1件: 8 8 |
473 | Bexarotene | 1件: Bexarotene Bexarotene | 1件: D03106
D03106
| 3件: RXRA RXRA, RXRB, RXRG 💬 | 17件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Bile secretion, Chemical carcinogenesis - receptor activation, Gastric cancer, Hepatitis C, Lipid and atherosclerosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer 💬 | 2件: 13 13, 75 |
474 | Bexsero | 1件: Neisseria meningitidis serogroup b nhba fusion protein antigen Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 6件: 11 11, 13, 61, 62, 66, 222 |
475 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA P | 1件: Neisseria meningitidis serogroup b nhba fusion protein antigen Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 1件: 62 62 |
476 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO | 1件: Neisseria meningitidis serogroup b nhba fusion protein antigen Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 1件: 66 66 |
477 | BEXSERO – Sospensione iniettabile – Siringa preriempita | 1件: Neisseria meningitidis serogroup b nhba fusion protein antigen Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 2件: 61 61, 62 |
478 | Bezafibrat | - | - | - | - | 1件: 93 93 |
479 | Bezafibrat Genericon retard 400 mg | - | - | - | - | 1件: 93 93 |
480 | Bezafibrate | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 7件: 20 20, 93, 94, 160, 296, 316, 324 |
481 | Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy | 2件: Bezafibrate Bezafibrate, Ursodeoxycholic acid | 2件: D00734
D00734
,
D01366
| 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 |
482 | Bezafibrate (drug) | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 316 316 |
483 | Bezafibrate (INN 3968) | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 324 324 |
484 | Bezafibrate 100 MG | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
485 | Bezafibrate 200 MG | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
486 | Bezafibrate 200 MG Oral Tablet | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
487 | Bezafibrate 400 MG | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
488 | Bezafibrate IR | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
489 | Bezafibrate SR | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
490 | Bezafibrate, Beza, BZF, Bezalip | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
491 | Bezafibrate, Beza, BZF, Bezalip mono | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
492 | Bezalip | - | - | - | - | 3件: 93 93, 94, 160 |
493 | Bezalip mono | - | - | - | - | 1件: 93 93 |
494 | Bezalip Retard | - | - | - | - | 1件: 160 160 |
495 | Bezlotoxumab | 1件: Bezlotoxumab Bezlotoxumab | 1件: D10453
D10453
| - | - | 2件: 96 96, 97 |
496 | BF 2.649 | - | - | - | - | 1件: 6 6 |
497 | BF 2.649 10 mg | - | - | - | - | 1件: 6 6 |
498 | BF 2.649 20 mg | - | - | - | - | 1件: 6 6 |
499 | BF 2.649 40 mg | - | - | - | - | 1件: 6 6 |
500 | BF 2.649 5 mg | - | - | - | - | 1件: 6 6 |
501 | BF2.649 | - | - | - | - | 1件: 6 6 |
502 | BF2.649 (Pitolisant) | 1件: Pitolisant Pitolisant | 1件: D10749
D10749
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
503 | BFAHF-2 | - | - | - | - | 1件: 96 96 |
504 | BFGF | 1件: Basic Fibroblast Growth Factor Basic Fibroblast Growth Factor | - | - | - | 1件: 56 56 |
505 | BG-12 120 | - | - | - | - | 1件: 13 13 |
506 | BG00002 | - | - | - | - | 1件: 13 13 |
507 | BG00002 (natalizumab) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
508 | BG00002-E (natalizumab high titer) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
509 | BG00011 | - | - | - | - | 1件: 85 85 |
510 | BG00012 | - | - | - | - | 2件: 13 13, 46 |
511 | BG00012 (DMF) | - | - | - | - | 1件: 13 13 |
512 | BG00012 (DMF) (Tecfidera®.) | - | - | - | - | 1件: 13 13 |
513 | BG0002 (natalizumab) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
514 | BG9418 (interferon beta 1-a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
515 | BG9418 (interferon beta-1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 13 13, 97 |
516 | BG9924 | - | - | - | - | 2件: 46 46, 97 |
517 | BGC20-0134 | - | - | - | - | 1件: 13 13 |
518 | BGG492 | - | - | - | - | 1件: 13 13 |
519 | BGJ398 | - | - | - | - | 1件: 238 238 |
520 | BGJ398 (also known as BBP-831) | - | - | - | - | 1件: 276 276 |
521 | BGP-014 | - | - | - | - | 1件: 97 97 |
522 | BGP-014 Capsules | - | - | - | - | 1件: 97 97 |
523 | BGX-0214 | - | - | - | - | 1件: 46 46 |
524 | BH4 | - | - | - | - | 5件: 51 51, 86, 124, 240, 299 |
525 | BH4 20mg | - | - | - | - | 1件: 299 299 |
526 | BH4 5mg | - | - | - | - | 1件: 299 299 |
527 | BHP001 | - | - | - | - | 1件: 19 19 |
528 | BHT-3009 | - | - | - | - | 1件: 13 13 |
529 | BHT-3009 0.5 mg | - | - | - | - | 1件: 13 13 |
530 | BHT-3009 1.5 mg | - | - | - | - | 1件: 13 13 |
531 | BHT-3009-01 | - | - | - | - | 1件: 13 13 |
532 | BHV-0223 | - | - | - | - | 1件: 2 2 |
533 | BHV-3241 | - | - | - | - | 1件: 17 17 |
534 | BHV-4157 | - | - | - | - | 1件: 17 17 |
535 | BI 1015550 | - | - | - | - | 1件: 85 85 |
536 | BI 1265162 | - | - | - | - | 1件: 299 299 |
537 | BI 1265162 10 µg | - | - | - | - | 1件: 299 299 |
538 | BI 1265162 100 µg | - | - | - | - | 1件: 299 299 |
539 | BI 1265162 25 µg | - | - | - | - | 1件: 299 299 |
540 | BI 1265162 50 µg | - | - | - | - | 1件: 299 299 |
541 | BI 1323495 | - | - | - | - | 1件: 299 299 |
542 | BI 443651 | - | - | - | - | 1件: 299 299 |
543 | BI 655064 | - | - | - | - | 1件: 46 46 |
544 | BI 655064 high dose | - | - | - | - | 1件: 46 46 |
545 | BI 655064 low dose | - | - | - | - | 1件: 46 46 |
546 | BI 655064 medium dose | - | - | - | - | 1件: 46 46 |
547 | BI 655066 | - | - | - | - | 2件: 96 96, 271 |
548 | BI 655066 10 mg/ml | - | - | - | - | 1件: 96 96 |
549 | BI 655066 90 mg/ml | - | - | - | - | 2件: 96 96, 271 |
550 | BI 655130 | - | - | - | - | 3件: 37 37, 96, 97 |
551 | BI 695500 | - | - | - | - | 1件: 46 46 |
552 | BI 695501 | - | - | - | - | 2件: 46 46, 96 |
553 | BI 695501 Autoinjector | - | - | - | - | 1件: 46 46 |
554 | BI 695501 Prefilled syringe | - | - | - | - | 1件: 46 46 |
555 | BI 705564 | - | - | - | - | 1件: 49 49 |
556 | BI 706321 | - | - | - | - | 1件: 96 96 |
557 | BI 730357 | - | - | - | - | 1件: 271 271 |
558 | BI 764198 | - | - | - | - | 1件: 222 222 |
559 | BI-Sifrol® | - | - | - | - | 1件: 6 6 |
560 | BI655130 | - | - | - | - | 1件: 37 37 |
561 | BIA | 1件: BIA BIA | - | - | - | 2件: 6 6, 86 |
562 | BIA 3-202 | 1件: BIA BIA | - | - | - | 1件: 6 6 |
563 | BIA 3-202 (200 mg) | 1件: BIA BIA | - | - | - | 1件: 6 6 |
564 | BIA 5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 |
565 | BIA 6-512 | 1件: BIA BIA | - | - | - | 1件: 6 6 |
566 | BIA 6-512 100 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 |
567 | BIA 6-512 100 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 |
568 | BIA 6-512 200 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 |
569 | BIA 6-512 25 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 |
570 | BIA 6-512 25 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 |
571 | BIA 6-512 400 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 |
572 | BIA 6-512 50 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 |
573 | BIA 9-1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 |
574 | BIA 9-1067 (test) | 1件: BIA BIA | - | - | - | 1件: 6 6 |
575 | BIA 9-1067 15 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 |
576 | BIA 9-1067 25 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 |
577 | BIA 9-1067 30 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 |
578 | BIA 9-1067 5 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 |
579 | BIA 9-1067 micronized | 1件: BIA BIA | - | - | - | 1件: 6 6 |
580 | BIA 9-1067 non-micronized | 1件: BIA BIA | - | - | - | 1件: 6 6 |
581 | BIA-5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 |
582 | BIAP | - | - | - | - | 2件: 46 46, 97 |
583 | Biaxin ( clarithromycin) | 1件: Clarithromycin Clarithromycin | 1件: D00276
D00276
| - | - | 1件: 299 299 |
584 | BIBF 1120 | - | - | - | - | 2件: 51 51, 85 |
585 | BIBF 1120 ES | - | - | - | - | 1件: 85 85 |
586 | BIBF1120 | - | - | - | - | 1件: 85 85 |
587 | BIBR 796 BS | - | - | - | - | 1件: 46 46 |
588 | BIBR 796 BS, 20 mg | - | - | - | - | 1件: 96 96 |
589 | BIBR 796 BS, 5 mg | - | - | - | - | 1件: 96 96 |
590 | Bicain spinal | - | - | - | - | 1件: 46 46 |
591 | Bicarbonate Ringer's solution | - | - | - | - | 1件: 296 296 |
592 | Bif195 capsules | - | - | - | - | 1件: 96 96 |
593 | Bifico | - | - | - | - | 1件: 291 291 |
594 | Bifidobacterium breve | 1件: Bifidobacterium breve Bifidobacterium breve | - | - | - | 1件: 97 97 |
595 | Bifidobacterium infantis | 1件: Bifidobacterium longum infantis Bifidobacterium longum infantis | - | - | - | 2件: 96 96, 97 |
596 | Bifidobacterium infantis 35624 | 1件: Bifidobacterium longum infantis Bifidobacterium longum infantis | - | - | - | 2件: 96 96, 97 |
597 | BIIB 017 | - | - | - | - | 1件: 13 13 |
598 | BIIB014 | - | - | - | - | 1件: 6 6 |
599 | BIIB017 | - | - | - | - | 1件: 13 13 |
600 | BIIB017 (Peginterferon beta-1a) | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
601 | BIIB017 (peginterferon beta-1a) Autoinjector | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
602 | BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS) | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
603 | BIIB019 | - | - | - | - | 1件: 13 13 |
604 | BIIB019 (Daclizumab High Yield Process) | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
605 | BIIB019 (Daclizumab) | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
606 | BIIB023 | - | - | - | - | 1件: 46 46 |
607 | BIIB033 | - | - | - | - | 1件: 13 13 |
608 | BIIB033 (ANTI-LINGO) | - | - | - | - | 1件: 13 13 |
609 | BIIB033 (ANTI-LINGO) - EV Substance Code SUB118957 | - | - | - | - | 1件: 13 13 |
610 | BIIB033 (opicinumab) | 1件: Opicinumab Opicinumab | 1件: D11767
D11767
| 1件: LINGO1 LINGO1 💬 | - | 1件: 13 13 |
611 | BIIB041 | - | - | - | - | 1件: 13 13 |
612 | BIIB041 (fampridine) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
613 | BIIB041 (Fampridine-SR) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
614 | BIIB041 (PR Fampridine) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
615 | BIIB050 / KNS-760704 | - | - | - | - | 1件: 2 2 |
616 | BIIB050/KNS-760704 | - | - | - | - | 1件: 2 2 |
617 | BIIB054 | - | - | - | - | 1件: 6 6 |
618 | BIIB057 | - | - | - | - | 1件: 46 46 |
619 | BIIB059 | - | - | - | - | 1件: 49 49 |
620 | BIIB061 | - | - | - | - | 1件: 13 13 |
621 | BIIB067 | - | - | - | - | 1件: 2 2 |
622 | BIIB067 (ISIS666853) | - | - | - | - | 1件: 2 2 |
623 | BIIB067 (Tofersen) | 1件: Tofersen Tofersen | 1件: D11811
D11811
| 1件: SOD1 SOD1 💬 | 8件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Chemical carcinogenesis - reactive oxygen species, Huntington disease, Longevity regulating pathway - multiple species, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Peroxisome, Prion disease 💬 | 1件: 2 2 |
624 | BIIB078 | - | - | - | - | 1件: 2 2 |
625 | BIIB092 | - | - | - | - | 3件: 5 5, 7, 127 |
626 | BIIB094 | - | - | - | - | 1件: 6 6 |
627 | BIIB100 | - | - | - | - | 1件: 2 2 |
628 | BIIB101 | - | - | - | - | 1件: 17 17 |
629 | BIIB105 | - | - | - | - | 1件: 2 2 |
630 | BIIB112 | - | - | - | - | 1件: 90 90 |
631 | BIIB133 | - | - | - | - | 1件: 13 13 |
632 | BIIL 283 BS (Amelubent) | - | - | - | - | 1件: 299 299 |
633 | BIIL 284 BS high dose | - | - | - | - | 1件: 46 46 |
634 | BIIL 284 BS low dose | - | - | - | - | 1件: 46 46 |
635 | BIIL 284 BS medium dose | - | - | - | - | 1件: 46 46 |
636 | BIIL 284 BS, high dose | - | - | - | - | 1件: 299 299 |
637 | BIIL 284 BS, high dose, adult patients | - | - | - | - | 1件: 299 299 |
638 | BIIL 284 BS, high dose, pediatric patients | - | - | - | - | 1件: 299 299 |
639 | BIIL 284 BS, low dose | - | - | - | - | 1件: 299 299 |
640 | BIIL 284 BS, low dose, adult patients | - | - | - | - | 1件: 299 299 |
641 | BIIL 284 BS, low dose, pediatric patients | - | - | - | - | 1件: 299 299 |
642 | BIIL 284 BS, medium dose, adult patients | - | - | - | - | 1件: 299 299 |
643 | BIIL 284 BS, medium dose, pediatric patients | - | - | - | - | 1件: 299 299 |
644 | Biklin | - | - | - | - | 1件: 299 299 |
645 | Bilateral transforaminal epidural steroid injections | - | - | - | - | 1件: 70 70 |
646 | Biliary stent | - | - | - | - | 1件: 300 300 |
647 | BIM 23014 | - | - | - | - | 1件: 67 67 |
648 | Bimagrumab | 1件: Bimagrumab Bimagrumab | 1件: D10620
D10620
| 2件: ACVR2A ACVR2A, ACVR2B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 15 15 |
649 | BIMEKIZUMAB | 1件: Bimekizumab Bimekizumab | 1件: D11550
D11550
| 2件: IL17A IL17A, IL17F 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 3件: 46 46, 97, 271 |
650 | Binimetinib | 1件: Binimetinib Binimetinib | 1件: D10604
D10604
| 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 |
651 | BINOCRIT*1SIR 40000UI/1ML | 1件: Erythropoietin Erythropoietin | 1件: D03231
D03231
| 1件: EPOR EPOR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 18 18 |
652 | Binyrebarkhormon | - | - | - | - | 1件: 46 46 |
653 | Binyrebsrkhormon | - | - | - | - | 1件: 46 46 |
654 | Bio-25 probiotic | - | - | - | - | 1件: 299 299 |
655 | Bio-enhanced Curcumin Soft Gelatin Capsule | 2件: Curcumin Curcumin, Gelatin | 2件: D00115
D00115
,
D06892
| - | - | 1件: 97 97 |
656 | BIO101 | - | - | - | - | 1件: 113 113 |
657 | Bioactive Glass-Ceramic Spacer | - | - | - | - | 1件: 70 70 |
658 | Biocarn | - | - | - | - | 1件: 3 3 |
659 | Biochemical analysis of different bone markers. | - | - | - | - | 1件: 172 172 |
660 | Biodmards | - | - | - | - | 1件: 46 46 |
661 | Biofluid samplings | - | - | - | - | 1件: 6 6 |
662 | Biologic Agents | - | - | - | - | 1件: 46 46 |
663 | Biologic DMARD | - | - | - | - | 2件: 46 46, 271 |
664 | Biologic TNFi | - | - | - | - | 1件: 46 46 |
665 | Biologic/targeted therapy | - | - | - | - | 1件: 46 46 |
666 | Biologic: IC14 (monoclonal antibody against human CD14) | - | - | - | - | 1件: 2 2 |
667 | Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 |
668 | Biological agents | - | - | - | - | 1件: 46 46 |
669 | Biological assays | - | - | - | - | 1件: 19 19 |
670 | Biological assessment | - | - | - | - | 1件: 61 61 |
671 | Biological disease-modifying antirheumatic drugs (bDMARDs) | - | - | - | - | 1件: 46 46 |
672 | Biological DMARDs | - | - | - | - | 2件: 86 86, 107 |
673 | Biological Drug | - | - | - | - | 2件: 46 46, 97 |
674 | Biological samples | - | - | - | - | 1件: 13 13 |
675 | Biological sampling | - | - | - | - | 1件: 65 65 |
676 | Biological samplings | - | - | - | - | 1件: 96 96 |
677 | Biological/Vaccine: Allogeneic HB-adMSCs | 1件: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins | - | - | - | 1件: 6 6 |
678 | Biological: Benralizumab, Biological: Placebo to Mepolizumab | 2件: Benralizumab Benralizumab, Mepolizumab | 2件: D04923
D04923
,
D09874
| 2件: IL5 IL5, IL5RA 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 |
679 | Biological: Etanercept and its biosimilars | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 |
680 | Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 |
681 | Biological: Mepolizumab, Biological: Placebo to Benralizumab | 2件: Benralizumab Benralizumab, Mepolizumab | 2件: D04923
D04923
,
D09874
| 2件: IL5 IL5, IL5RA 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 |
682 | Biological: mesenchymal stem cell | - | - | - | - | 1件: 93 93 |
683 | Biological: SM03 | - | - | - | - | 1件: 46 46 |
684 | Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell | - | - | - | - | 1件: 113 113 |
685 | Biologically active human fecal microbiota | - | - | - | - | 1件: 97 97 |
686 | Biologics | - | - | - | - | 1件: 46 46 |
687 | BION-1301 Multiple Doses | - | - | - | - | 1件: 66 66 |
688 | BION-1301 Single Dose | - | - | - | - | 1件: 66 66 |
689 | BIOOPA dressing | - | - | - | - | 1件: 36 36 |
690 | Biopsies | - | - | - | - | 1件: 97 97 |
691 | Biopsy | - | - | - | - | 4件: 19 19, 51, 78, 193 |
692 | Biopsy of the labial salivary gland | - | - | - | - | 1件: 53 53 |
693 | Biosimilar | - | - | - | - | 4件: 46 46, 96, 97, 271 |
694 | Biosimilar adalimumab | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 |
695 | Biosimilar Etanercept | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 |
696 | Biosimilar Infliximab | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 96, 97 |
697 | Biosimilar product to adalimumab | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
698 | Biospecimen Collection | - | - | - | - | 2件: 97 97, 159 |
699 | BioStamp nPoint device | - | - | - | - | 1件: 8 8 |
700 | Biostate | - | - | - | - | 1件: 288 288 |
701 | Biostate® | - | - | - | - | 1件: 288 288 |
702 | BIOTIN | 1件: Biotin Biotin | 1件: D00029
D00029
| - | - | 5件: 2 2, 8, 10, 13, 20 |
703 | Biotina | 1件: Biotin Biotin | 1件: D00029
D00029
| - | - | 2件: 8 8, 13 |
704 | BIRB 796 BS, high dose | - | - | - | - | 1件: 46 46 |
705 | BIRB 796 BS, low dose | - | - | - | - | 1件: 46 46 |
706 | BIRCH BARK EXTRACT | 1件: Birch bark extract Birch bark extract | - | - | - | 1件: 36 36 |
707 | BIRT 2584 XX | - | - | - | - | 1件: 13 13 |
708 | BIRT 2584XX | - | - | - | - | 1件: 13 13 |
709 | BIRTAMIMAB | 1件: Birtamimab Birtamimab | 1件: D11373
D11373
| - | - | 1件: 28 28 |
710 | BIS-CHOLINE TETRATHIOMOLYBDATE | 2件: Choline Choline, Tetrathiomolybdate | 1件: D07690
D07690
| - | - | 1件: 171 171 |
711 | BIS-CHOLINE TETRATHIOMOLYBDATE, bis[(2-Hydroxyethyl)trimethylammonium] tetrathiomolybdate | 2件: Choline Choline, Tetrathiomolybdate | 1件: D07690
D07690
| - | - | 1件: 171 171 |
712 | Bisacodyl | 1件: Bisacodyl Bisacodyl | 1件: D00245
D00245
| - | - | 1件: 13 13 |
713 | BISOPROLOL | 1件: Bisoprolol Bisoprolol | 2件: D00634
D00634
,
D02342
| 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 67 67, 86, 113 |
714 | Bisoprolol Fumarate | 1件: Bisoprolol Bisoprolol | 2件: D00634
D00634
,
D02342
| 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 113 113 |
715 | Bisphosphonate treatment | - | - | - | - | 2件: 113 113, 299 |
716 | Bisphosphonates | - | - | - | - | 2件: 6 6, 274 |
717 | BITTER CANDYTUFT FRESH PLANT EXTRACT | - | - | - | - | 1件: 97 97 |
718 | Bitterschleifenblume-ganzpflanze 1,5ml/10ml | - | - | - | - | 1件: 97 97 |
719 | BIV009 | - | - | - | - | 2件: 61 61, 162 |
720 | Bivigam | - | - | - | - | 1件: 65 65 |
721 | BIVV001 (rFVIIIFc-VWF-XTEN) | - | - | - | - | 1件: 288 288 |
722 | BIVV009 | - | - | - | - | 1件: 61 61 |
723 | BIVV020 | - | - | - | - | 2件: 14 14, 61 |
724 | BIVV020/SAR445088 | - | - | - | - | 1件: 14 14 |
725 | BL-7040 | - | - | - | - | 1件: 97 97 |
726 | BL-8040 | - | - | - | - | 1件: 60 60 |
727 | Bladder instillation with heparin/ lidocaine | 2件: Heparin Heparin, Lidocaine | 4件: D00358
D00358
,
D02086
,
D07510
,
D08127
| 6件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 | 4件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬 | 1件: 226 226 |
728 | Bladder instillation WITH triamcinolone acetonide | 1件: Triamcinolone Triamcinolone | 5件: D00385
D00385
,
D00983
,
D00984
,
D00985
,
D06216
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 226 226 |
729 | Bladder instillation WITHOUT triamcinolone acetonide | 1件: Triamcinolone Triamcinolone | 5件: D00385
D00385
,
D00983
,
D00984
,
D00985
,
D06216
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 226 226 |
730 | Bladder Instillations | - | - | - | - | 1件: 226 226 |
731 | Blarcamesine | 1件: Blarcamesine Blarcamesine | 1件: D11383
D11383
| 6件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SIGMAR1 💬 | 14件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 156 156 |
732 | BLD-2660 | - | - | - | - | 1件: 85 85 |
733 | Bleomycin | 1件: Bleomycin Bleomycin | 3件: D02177
D02177
,
D03229
,
D07535
| - | - | 4件: 96 96, 278, 279, 280 |
734 | Bleomycin + Fibrovein | 1件: Bleomycin Bleomycin | 3件: D02177
D02177
,
D03229
,
D07535
| - | - | 1件: 279 279 |
735 | Bleomycin Baxter | 1件: Bleomycin Bleomycin | 3件: D02177
D02177
,
D03229
,
D07535
| - | - | 1件: 279 279 |
736 | Bleselumab | 1件: Bleselumab Bleselumab | 1件: D11357
D11357
| 1件: CD40 CD40 💬 | 17件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Intestinal immune network for IgA production, Lipid and atherosclerosis, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis 💬 | 1件: 222 222 |
737 | BLF | - | - | - | - | 1件: 299 299 |
738 | BLI-1300 high dose | - | - | - | - | 1件: 96 96 |
739 | BLI-1300 low dose | - | - | - | - | 1件: 96 96 |
740 | Blinded (Avatrombopoag tablets) | - | - | - | - | 1件: 63 63 |
741 | Blinded CDCA 250 mg TID | 1件: Chenodeoxycholic acid Chenodeoxycholic acid | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 |
742 | Blisibimod | 1件: Blisibimod Blisibimod | 1件: D10311
D10311
| - | - | 5件: 43 43, 44, 49, 63, 66 |
743 | Blisibimod Injection | 1件: Blisibimod Blisibimod | 1件: D10311
D10311
| - | - | 1件: 66 66 |
744 | Blokium 50 | - | - | - | - | 1件: 167 167 |
745 | BLOKIUM 50 mg comprimidos | - | - | - | - | 1件: 167 167 |
746 | Blood | - | - | - | - | 1件: 46 46 |
747 | Blood analysis | - | - | - | - | 1件: 6 6 |
748 | Blood and stools samples | - | - | - | - | 1件: 96 96 |
749 | Blood coagulation Factor VIII and vWF, human | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 |
750 | Blood coagulation factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 51 51 |
751 | Blood collection | - | - | - | - | 2件: 229 229, 271 |
752 | Blood Collection for PK Testing (15 Mins Before Injection) | - | - | - | - | 1件: 46 46 |
753 | Blood Collection for PK Testing (15 minutes post injection) | - | - | - | - | 1件: 46 46 |
754 | Blood Collection for PK Testing (18-20 hours post injection) | - | - | - | - | 1件: 46 46 |
755 | Blood Collection for PK Testing (180 minutes post injection) | - | - | - | - | 1件: 46 46 |
756 | Blood Collection for PK Testing (60 minutes post injection) | - | - | - | - | 1件: 46 46 |
757 | Blood Collection for PK Testing (after injection) | - | - | - | - | 1件: 46 46 |
758 | Blood draw | - | - | - | - | 5件: 6 6, 19, 65, 231, 299 |
759 | Blood draw for the laboratory assessment | - | - | - | - | 1件: 303 303 |
760 | Blood draw. | - | - | - | - | 2件: 231 231, 299 |
761 | Blood draws | - | - | - | - | 1件: 78 78 |
762 | Blood pressure | - | - | - | - | 1件: 84 84 |
763 | Blood sample | - | - | - | - | 18件: 8 8, 13, 46, 49, 51, 53, 61, 65, 66, 84, 96, 97, 107, 127, 235, 274, 288, 299 |
764 | Blood sample and environmental survey | - | - | - | - | 1件: 2 2 |
765 | Blood sample collection | - | - | - | - | 1件: 85 85 |
766 | Blood samples | - | - | - | - | 9件: 13 13, 41, 46, 51, 61, 97, 227, 240, 271 |
767 | Blood sampling | - | - | - | - | 6件: 13 13, 17, 19, 46, 51, 96 |
768 | Blood sampling before | - | - | - | - | 1件: 78 78 |
769 | Blood sampling for determination of serum Zn | - | - | - | - | 1件: 299 299 |
770 | Blood sampling from infant | - | - | - | - | 3件: 46 46, 96, 271 |
771 | Blood sampling from mother | - | - | - | - | 3件: 46 46, 96, 271 |
772 | Blood sampling from umbilical cord | - | - | - | - | 3件: 46 46, 96, 271 |
773 | Blood sampling, endoscopy | - | - | - | - | 1件: 97 97 |
774 | Blood test | - | - | - | - | 6件: 36 36, 51, 86, 113, 162, 299 |
775 | Blood tests | - | - | - | - | 2件: 46 46, 263 |
776 | BLS-M22 | - | - | - | - | 1件: 113 113 |
777 | Blue light photopheresis | - | - | - | - | 1件: 96 96 |
778 | Blue light-absorbing sunglasses | - | - | - | - | 1件: 90 90 |
779 | Bluefish | 1件: Bluefish Bluefish | - | - | - | 1件: 58 58 |
780 | BLZ945 | - | - | - | - | 1件: 2 2 |
781 | BM110 | - | - | - | - | 1件: 19 19 |
782 | BMDex | - | - | - | - | 1件: 28 28 |
783 | BMMNC | - | - | - | - | 1件: 13 13 |
784 | BMMNCs | - | - | - | - | 1件: 90 90 |
785 | BMN 044 | - | - | - | - | 1件: 113 113 |
786 | BMN 044 IV 6 mg/kg | - | - | - | - | 1件: 113 113 |
787 | BMN 044 IV 9 mg/kg | - | - | - | - | 1件: 113 113 |
788 | BMN 044 SC 6 mg/kg | - | - | - | - | 1件: 113 113 |
789 | BMN 045 | - | - | - | - | 1件: 113 113 |
790 | BMN 053 | - | - | - | - | 1件: 113 113 |
791 | BMN 110 | - | - | - | - | 1件: 19 19 |
792 | BMN 110 - Every Other Week | - | - | - | - | 1件: 19 19 |
793 | BMN 110 - Weekly | - | - | - | - | 1件: 19 19 |
794 | BMN 110 Every Other Week | - | - | - | - | 1件: 19 19 |
795 | BMN 110 Weekly | - | - | - | - | 1件: 19 19 |
796 | BMN 111 | - | - | - | - | 1件: 276 276 |
797 | BMN 165 | - | - | - | - | 1件: 240 240 |
798 | BMN 165 (rAvPAL-PEG) | 1件: Pegvaliase Pegvaliase | 1件: D11077
D11077
| 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 |
799 | BMN 190 | - | - | - | - | 1件: 19 19 |
800 | BMN 250 | - | - | - | - | 1件: 19 19 |
801 | BMN 307 | - | - | - | - | 1件: 240 240 |
802 | BMN 701 | - | - | - | - | 1件: 256 256 |
803 | BMN053 | - | - | - | - | 1件: 113 113 |
804 | BMN165 20mg/day | - | - | - | - | 1件: 240 240 |
805 | BMN165 40mg/day | - | - | - | - | 1件: 240 240 |
806 | BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1) | - | - | - | - | 1件: 19 19 |
807 | BMP-2 | 1件: Dibotermin alfa Dibotermin alfa | 1件: D03779
D03779
| 1件: BMPR2 BMPR2 💬 | 7件: Axon guidance Axon guidance, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hippo signaling pathway, MicroRNAs in cancer, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 34 34 |
808 | BMS 188667 (Abatacept) | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 12件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | 1件: 13 13 |
809 | BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin) | 5件: Digoxin Digoxin, Flurbiprofen, Midazolam, Montelukast, Omeprazole | 13件: D00298
D00298
,
D00330
,
D00455
,
D00529
,
D00550
,
D00696
,
D01207
,
D01475
,
D02290
,
D05028
,
D05259
,
D05261
,
D08229
| 25件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP4A, ATP4B, CYSLTR1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, PTGS1, PTGS2 💬 | 49件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Arachidonic acid metabolism, Bile secretion, C-type lectin receptor signaling pathway, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Chemical carcinogenesis - DNA adducts, Collecting duct acid secretion, Endocrine and other factor-regulated calcium reabsorption, GABAergic synapse, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Insulin secretion, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Nicotine addiction, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pancreatic secretion, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, Taste transduction, Thyroid hormone signaling pathway, Thyroid hormone synthesis, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 |
810 | BMS-188667 | - | - | - | - | 9件: 46 46, 49, 53, 65, 96, 97, 107, 222, 271 |
811 | BMS-232632 | - | - | - | - | 1件: 265 265 |
812 | BMS-582949 | 1件: BMS-582949 BMS-582949 | - | - | - | 1件: 46 46 |
813 | BMS-582949 and Methotrexate | 2件: BMS-582949 BMS-582949, Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
814 | BMS-817399 | 1件: BMS-817399 BMS-817399 | - | - | - | 1件: 46 46 |
815 | BMS-931699 | 1件: Lulizumab pegol Lulizumab pegol | - | - | - | 3件: 49 49, 53, 160 |
816 | BMS-936557 | - | - | - | - | 2件: 96 96, 97 |
817 | BMS-936557 (Anti-IP-10 Antibody) | - | - | - | - | 1件: 96 96 |
818 | BMS-945429 | 1件: Clazakizumab Clazakizumab | 1件: D10312
D10312
| - | - | 2件: 46 46, 96 |
819 | BMS-986004 | - | - | - | - | 1件: 63 63 |
820 | BMS-986004 1500 mg IV | - | - | - | - | 1件: 63 63 |
821 | BMS-986004 225 mg IV | - | - | - | - | 1件: 63 63 |
822 | BMS-986004 675 mg IV | - | - | - | - | 1件: 63 63 |
823 | BMS-986004 75 mg IV | - | - | - | - | 1件: 63 63 |
824 | BMS-986020 | 1件: BMS-986020 BMS-986020 | - | - | - | 2件: 51 51, 85 |
825 | BMS-986089 | - | - | - | - | 1件: 113 113 |
826 | BMS-986089-01 (RO7239361) , anti-myostatin | - | - | - | - | 1件: 113 113 |
827 | BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 |
828 | BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 |
829 | BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 |
830 | BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 |
831 | BMS-986089-01 (RO7239361), anti-myostatin | - | - | - | - | 1件: 113 113 |
832 | BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 |
833 | BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 |
834 | BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 |
835 | BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 |
836 | BMS-986089-01, Anti-myostatin | - | - | - | - | 1件: 113 113 |
837 | BMS-986104 | 1件: BMS-986104 BMS-986104 | - | - | - | 1件: 46 46 |
838 | BMS-986142 | 1件: BMS-986142 BMS-986142 | - | - | - | 3件: 46 46, 53, 160 |
839 | BMS-986142 200mg | 1件: BMS-986142 BMS-986142 | - | - | - | 1件: 46 46 |
840 | BMS-986142 350mg | 1件: BMS-986142 BMS-986142 | - | - | - | 1件: 46 46 |
841 | BMS-986165 | - | - | - | - | 3件: 49 49, 96, 97 |
842 | BMS-986165 Capsule | - | - | - | - | 1件: 49 49 |
843 | BMS-986165 Dose 1 | - | - | - | - | 1件: 97 97 |
844 | BMS-986165 Dose 2 | - | - | - | - | 1件: 97 97 |
845 | BMS-986165 Tablet | - | - | - | - | 1件: 49 49 |
846 | BMS-986166 | - | - | - | - | 1件: 97 97 |
847 | BMS-986168 | 1件: Gosuranemab Gosuranemab | 1件: D11293
D11293
| 1件: MAPT MAPT 💬 | 4件: Alzheimer disease Alzheimer disease, MAPK signaling pathway, Parkinson disease, Pathways of neurodegeneration - multiple diseases 💬 | 1件: 5 5 |
848 | BMS-986184 | - | - | - | - | 1件: 97 97 |
849 | BMS-986195 | 1件: Branebrutinib Branebrutinib | 1件: D11478
D11478
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 3件: 46 46, 49, 53 |
850 | BMS-986251 | - | - | - | - | 2件: 46 46, 271 |
851 | BMS-986256 | 1件: Afimetoran Afimetoran | 1件: D11908
D11908
| - | - | 1件: 49 49 |
852 | BMS-986256 (Oral) | 1件: Afimetoran Afimetoran | 1件: D11908
D11908
| - | - | 1件: 49 49 |
853 | BMS-986256-06, TLR7/8 Antagonist | 1件: Afimetoran Afimetoran | 1件: D11908
D11908
| - | - | 1件: 49 49 |
854 | BMS-986278 | - | - | - | - | 1件: 85 85 |
855 | BMS-986325 | - | - | - | - | 1件: 53 53 |
856 | BMS188667 | - | - | - | - | 1件: 46 46 |
857 | BMS986142 | - | - | - | - | 3件: 46 46, 53, 160 |
858 | BMS986165 | - | - | - | - | 2件: 96 96, 97 |
859 | BMS986168 | - | - | - | - | 1件: 5 5 |
860 | BMS986195 | - | - | - | - | 3件: 46 46, 49, 53 |
861 | BN82451B | - | - | - | - | 1件: 8 8 |
862 | BN8251B | - | - | - | - | 1件: 8 8 |
863 | BNJ441 | - | - | - | - | 1件: 66 66 |
864 | BNP | - | - | - | - | 2件: 46 46, 58 |
865 | BNP blood sample test | - | - | - | - | 1件: 58 58 |
866 | BNT162b2 | - | - | - | - | 5件: 13 13, 35, 46, 49, 51 |
867 | Bocidelpar | - | - | - | - | 1件: 113 113 |
868 | BodyBio Balance Oil | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
869 | BodyBio PC | - | - | - | - | 1件: 13 13 |
870 | Bof-, Mazelen-, Rubellavaccin, poeder voor injectievloeistof | - | - | - | - | 1件: 107 107 |
871 | Bone balance measurements | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 81 81 |
872 | Bone densitometry | - | - | - | - | 2件: 49 49, 162 |
873 | Bone marrow ablation with stem cell support | - | - | - | - | 2件: 28 28, 60 |
874 | Bone marrow aspiration | - | - | - | - | 2件: 60 60, 285 |
875 | Bone Marrow Aspiration and Biopsy | - | - | - | - | 1件: 28 28 |
876 | Bone marrow autologous mesenchymal stem cells transplantation | - | - | - | - | 1件: 13 13 |
877 | Bone Marrow Concentrate | - | - | - | - | 1件: 70 70 |
878 | Bone marrow derived mesenchymal stem cells | - | - | - | - | 2件: 6 6, 60 |
879 | Bone Marrow Derived Mesenchymal Stem cells (MSCs) | - | - | - | - | 1件: 96 96 |
880 | Bone marrow infusion | - | - | - | - | 1件: 36 36 |
881 | Bone marrow mesenchymal stem cells | - | - | - | - | 1件: 85 85 |
882 | Bone marrow mononuclear cells | - | - | - | - | 1件: 57 57 |
883 | Bone Marrow MSC Derived Extracellular Vesicle Isolate | - | - | - | - | 1件: 96 96 |
884 | Bone marrow or umbilical cord blood (UCG) stem cell transplantation | - | - | - | - | 1件: 36 36 |
885 | Bone Marrow Transplant | - | - | - | - | 2件: 60 60, 274 |
886 | Bone marrow transplantation | - | - | - | - | 4件: 51 51, 60, 284, 285 |
887 | Bone marrow-derived mesenchymal stem cells | - | - | - | - | 1件: 298 298 |
888 | Bonefos | 1件: Clodronic acid Clodronic acid | 2件: D03544
D03544
,
D03545
| - | - | 1件: 274 274 |
889 | BoNT-A | - | - | - | - | 1件: 6 6 |
890 | Bony Toxicity | - | - | - | - | 1件: 34 34 |
891 | BOOST cells | - | - | - | - | 1件: 274 274 |
892 | Boost VHC | - | - | - | - | 1件: 299 299 |
893 | Boostrix | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 |
894 | Boostrix® | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 |
895 | Boots High Strength Garlic Odour Controlled | 1件: Garlic Garlic | 1件: D12020
D12020
| - | - | 1件: 299 299 |
896 | BORAGE OIL | 1件: Borage oil Borage oil | - | - | - | 1件: 13 13 |
897 | BORAGE OIL 20% GLA | 1件: Borage oil Borage oil | - | - | - | 1件: 13 13 |
898 | Borage seed oil | - | - | - | - | 1件: 46 46 |
899 | BORTEZOMIB | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 16件: 11 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 |
900 | Bortezomib (Velcade®) | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 66 66 |
901 | Bortezomib Accord | 2件: Bortezomib Bortezomib, Bortezomib D-mannitol | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 |
902 | Bortezomib D-mannitol | 2件: Bortezomib Bortezomib, Mannitol | 2件: D00062
D00062
,
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 |
903 | Bortezomib Injection | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 64 64 |
904 | Bortezomib/dexamethasone | 2件: Bortezomib Bortezomib, Dexamethasone | 10件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
,
D03150
| 2件: NR3C1 NR3C1, PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 283 283 |
905 | Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone | 2件: Bortezomib Bortezomib, Dexamethasone | 10件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
,
D03150
| 2件: NR3C1 NR3C1, PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 |
906 | BOS161721 | - | - | - | - | 1件: 49 49 |
907 | Bosentan | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 11件: 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
908 | Bosentan (Tracleer) | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 |
909 | Bosentan 125 mg | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 |
910 | Bosentan 62.5 mg | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 |
911 | Bosentan administration | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
912 | Bosentan and Sildenafil | 2件: Bosentan Bosentan, Sildenafil | 4件: D01227
D01227
,
D02229
,
D07538
,
D08514
| 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
913 | Bosentan group | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 |
914 | BOSENTAN MONOHIDRATO | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
915 | Bosentan monohydrat | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
916 | BOSENTAN MONOHYDRATE | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 51 51, 84, 86, 88 |
917 | BOSENTAN MYLAN | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 41 41 |
918 | Bosentan, Ambrisentan | 2件: Ambrisentan Ambrisentan, Bosentan | 3件: D01227
D01227
,
D07077
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
919 | Bosutinib | 1件: Bosutinib Bosutinib | 1件: D03252
D03252
| 2件: ABL1 ABL1, SRC 💬 | 49件: Adherens junction Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬 | 2件: 2 2, 67 |
920 | Bosutinib (anhydrous) | 1件: Bosutinib Bosutinib | 1件: D03252
D03252
| 2件: ABL1 ABL1, SRC 💬 | 49件: Adherens junction Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬 | 1件: 67 67 |
921 | BOSWELAN | - | - | - | - | 1件: 13 13 |
922 | Boswellia Serrata | 1件: Indian frankincense Indian frankincense | - | - | - | 1件: 13 13 |
923 | Boswellia Serrata Extract | 1件: Indian frankincense Indian frankincense | - | - | - | 1件: 13 13 |
924 | Boswellia serrata extract PS0201Bo capsules | 1件: Indian frankincense Indian frankincense | - | - | - | 1件: 13 13 |
925 | Boswellic acids (BOSWELAN) | - | - | - | - | 1件: 13 13 |
926 | Botaretigene sparoparvovec | - | - | - | - | 1件: 90 90 |
927 | Botox | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 6件: 2 2, 6, 13, 51, 149, 226 |
928 | BOTOX 100 UNITES ALLERGAN (PR1) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 2 2 |
929 | Botox 100 UNT Injection | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
930 | BOTOX 100U in normal saline | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 226 226 |
931 | BOTOX 200U in normal saline | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 226 226 |
932 | Botox injection | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 2 2 |
933 | BOTOX® | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
934 | BOTOX® solution | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 51 51 |
935 | Botulinic toxin | - | - | - | - | 1件: 36 36 |
936 | Botulinum A toxin | - | - | - | - | 1件: 118 118 |
937 | Botulinum Neurotoxin | - | - | - | - | 1件: 226 226 |
938 | Botulinum Toxin | - | - | - | - | 3件: 6 6, 13, 149 |
939 | Botulinum toxin A | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 4件: 13 13, 51, 149, 226 |
940 | BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
941 | BOTULINUM TOXIN TYPE A | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 10件: 2 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
942 | Botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 70 70 |
943 | Botulinum Toxin Type A 200U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
944 | Botulinum Toxin Type A 300U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
945 | Botulinum toxin type A infiltrations | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
946 | Botulinum toxin type B | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: D02735
D02735
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 3件: 2 2, 6, 51 |
947 | Botulinum toxin type B (2500 units / vial) | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: D02735
D02735
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 51 51 |
948 | Botulinum toxin type B (Myobloc) | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: D02735
D02735
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 2件: 2 2, 6 |
949 | Botulinum toxin(Botox) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 51 51 |
950 | Botulinum Toxin: Xeomin | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 |
951 | Botulism Toxin Treatment | - | - | - | - | 1件: 161 161 |
952 | Boulardii | - | - | - | - | 2件: 96 96, 97 |
953 | Bovine intesastinal alkaline phosphatase (bIAP) | 1件: Alkaline Phosphatase Alkaline Phosphatase | - | - | - | 1件: 46 46 |
954 | Bovine intestinal alkaline phosphatase (BIAP) | 1件: Alkaline Phosphatase Alkaline Phosphatase | - | - | - | 1件: 97 97 |
955 | Bovine type I collagen | 1件: Bovine type I collagen Bovine type I collagen | - | - | - | 1件: 51 51 |
956 | Bovine-Calf Alkaline Phosphatase (BIAP) | 1件: Alkaline Phosphatase Alkaline Phosphatase | - | - | - | 1件: 97 97 |
957 | Bovine-Calf Alkaline Phosphatase BIAP | 1件: Alkaline Phosphatase Alkaline Phosphatase | - | - | - | 1件: 97 97 |
958 | BOW015 | - | - | - | - | 1件: 46 46 |
959 | BPA | - | - | - | - | 1件: 88 88 |
960 | BPLG-003 | - | - | - | - | 1件: 78 78 |
961 | BPN14770 | - | - | - | - | 1件: 206 206 |
962 | BPR277 | - | - | - | - | 1件: 160 160 |
963 | BPR277 ointment | - | - | - | - | 1件: 160 160 |
964 | BPR277 ointment (controlled application) | - | - | - | - | 1件: 160 160 |
965 | BPS-314d-MR | - | - | - | - | 1件: 86 86 |
966 | BPS-MR | - | - | - | - | 1件: 86 86 |
967 | BPS804 | - | - | - | - | 2件: 172 172, 274 |
968 | BPX-501 | - | - | - | - | 3件: 60 60, 285, 326 |
969 | BPX-501 cells | - | - | - | - | 3件: 60 60, 285, 326 |
970 | BPX-501 T cells | - | - | - | - | 4件: 65 65, 284, 285, 326 |
971 | BQ123 | - | - | - | - | 1件: 17 17 |
972 | BR-DIM | - | - | - | - | 1件: 49 49 |
973 | BR9001 | - | - | - | - | 1件: 46 46 |
974 | BR900A | - | - | - | - | 1件: 46 46 |
975 | Brain Magnetic Resonance Imaging (MRI) | - | - | - | - | 1件: 17 17 |
976 | Brain MRI/MRS/fMRI | - | - | - | - | 1件: 19 19 |
977 | Brain PET scan | - | - | - | - | 3件: 5 5, 7, 127 |
978 | BRAMICIL - 100 MG/ 2 ML SOLUZIONE INIETTABILE 10 FIALE DA 2 ML | - | - | - | - | 1件: 299 299 |
979 | Bramitob | - | - | - | - | 1件: 299 299 |
980 | BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML | - | - | - | - | 1件: 299 299 |
981 | Bramitob 300mg/4ml Nebuliser Solution | - | - | - | - | 1件: 299 299 |
982 | BRAMITOB*NEBUL 28F 300MG/4ML | - | - | - | - | 1件: 299 299 |
983 | BRAMITOB*NEBUL 56F 300MG/4ML | - | - | - | - | 1件: 299 299 |
984 | Bramitob® administered by PARI eFlow® rapid electronic nebulizer | - | - | - | - | 1件: 299 299 |
985 | Bramitob® administered by PARI LC® PLUS nebulizer | - | - | - | - | 1件: 299 299 |
986 | Branaplam | 1件: Branaplam Branaplam | - | - | - | 2件: 3 3, 8 |
987 | Branebrutinib | 1件: Branebrutinib Branebrutinib | 1件: D11478
D11478
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 3件: 46 46, 49, 53 |
988 | BRAZIKUMAB | 1件: Brazikumab Brazikumab | 1件: D10912
D10912
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 96 96, 97 |
989 | Brazikumab high dose | 1件: Brazikumab Brazikumab | 1件: D10912
D10912
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 |
990 | Brazikumab Induction Dose | 1件: Brazikumab Brazikumab | 1件: D10912
D10912
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 96 96, 97 |
991 | Brazikumab IV Infusion | 1件: Brazikumab Brazikumab | 1件: D10912
D10912
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 |
992 | Brazikumab low dose | 1件: Brazikumab Brazikumab | 1件: D10912
D10912
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 |
993 | Brazikumab Maintenance Dose | 1件: Brazikumab Brazikumab | 1件: D10912
D10912
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 96 96, 97 |
994 | Brazikumab SC Injection | 1件: Brazikumab Brazikumab | 1件: D10912
D10912
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 |
995 | Break in L-carnitine treatment | 1件: Levocarnitine Levocarnitine | 3件: D02030
D02030
,
D02176
,
D04713
| - | - | 1件: 316 316 |
996 | Breast milk sampling | - | - | - | - | 3件: 46 46, 96, 271 |
997 | BREDININ | 1件: Mizoribine Mizoribine | 1件: D01392
D01392
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 1件: 46 46 |
998 | Bredinin tablet 150mg | 1件: Mizoribine Mizoribine | 1件: D01392
D01392
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 1件: 46 46 |
999 | Bredinin tablet 50mg | 1件: Mizoribine Mizoribine | 1件: D01392
D01392
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 1件: 46 46 |
1000 | Breelib nebulizer | - | - | - | - | 1件: 86 86 |
1001 | Brensocatib | 1件: Brensocatib Brensocatib | 1件: D12120
D12120
| 1件: CTSC CTSC 💬 | 2件: Apoptosis Apoptosis, Lysosome 💬 | 1件: 299 299 |
1002 | Brensocatib 10 mg | 1件: Brensocatib Brensocatib | 1件: D12120
D12120
| 1件: CTSC CTSC 💬 | 2件: Apoptosis Apoptosis, Lysosome 💬 | 1件: 299 299 |
1003 | Brensocatib 25 mg | 1件: Brensocatib Brensocatib | 1件: D12120
D12120
| 1件: CTSC CTSC 💬 | 2件: Apoptosis Apoptosis, Lysosome 💬 | 1件: 299 299 |
1004 | Brentuximab | 1件: Brentuximab vedotin Brentuximab vedotin | 1件: D09587
D09587
| 10件: TNFRSF8 TNFRSF8, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 11件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 2件: 49 49, 51 |
1005 | Brentuximab vedotin | 1件: Brentuximab vedotin Brentuximab vedotin | 1件: D09587
D09587
| 10件: TNFRSF8 TNFRSF8, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 11件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 2件: 49 49, 51 |
1006 | Brepocitinib | - | - | - | - | 1件: 49 49 |
1007 | Brepocitinib 25 mg | - | - | - | - | 2件: 96 96, 97 |
1008 | Brepocitinib 5 mg | - | - | - | - | 2件: 96 96, 97 |
1009 | Brepocitinib 5mg | - | - | - | - | 1件: 96 96 |
1010 | Brigatinib | 1件: Brigatinib Brigatinib | 1件: D10866
D10866
| 1件: ALK ALK 💬 | 3件: Non-small cell lung cancer Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer 💬 | 1件: 34 34 |
1011 | Brimonidine | 1件: Brimonidine Brimonidine | 2件: D02076
D02076
,
D07540
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 2件: 13 13, 90 |
1012 | Brimonidine tartrate | 1件: Brimonidine Brimonidine | 2件: D02076
D02076
,
D07540
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 2件: 13 13, 90 |
1013 | Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System | 1件: Brimonidine Brimonidine | 2件: D02076
D02076
,
D07540
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 90 90 |
1014 | Brineura | 1件: Cerliponase alfa Cerliponase alfa | 1件: D10813
D10813
| 1件: TPP1 TPP1 💬 | 1件: Lysosome Lysosome 💬 | 1件: 19 19 |
1015 | Brivaracetam | 1件: Brivaracetam Brivaracetam | 1件: D08879
D08879
| 1件: SV2A SV2A 💬 | 1件: ECM-receptor interaction ECM-receptor interaction 💬 | 2件: 149 149, 309 |
1016 | Brivaracetam 25 mg | 1件: Brivaracetam Brivaracetam | 1件: D08879
D08879
| 1件: SV2A SV2A 💬 | 1件: ECM-receptor interaction ECM-receptor interaction 💬 | 1件: 309 309 |
1017 | Brivaracetam 50 mg | 1件: Brivaracetam Brivaracetam | 1件: D08879
D08879
| 1件: SV2A SV2A 💬 | 1件: ECM-receptor interaction ECM-receptor interaction 💬 | 1件: 309 309 |
1018 | BRL-049653 | - | - | - | - | 1件: 46 46 |
1019 | Broccoli | 1件: Broccoli Broccoli | - | - | - | 3件: 36 36, 97, 299 |
1020 | Broccoli sprouts | 1件: Broccoli Broccoli | - | - | - | 1件: 299 299 |
1021 | Brodalumab | 1件: Brodalumab Brodalumab | 1件: D10061
D10061
| 1件: IL17RA IL17RA 💬 | 3件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway 💬 | 2件: 37 37, 51 |
1022 | Brodalumab 210mg SC | 1件: Brodalumab Brodalumab | 1件: D10061
D10061
| 1件: IL17RA IL17RA 💬 | 3件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway 💬 | 1件: 37 37 |
1023 | BROMOCRIPTINE | 1件: Bromocriptine Bromocriptine | 2件: D00780
D00780
,
D03165
| 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 2件: 6 6, 74 |
1024 | Bromocriptine and other dopamine agonists | 2件: Bromocriptine Bromocriptine, Dopamine | 4件: D00633
D00633
,
D00780
,
D03165
,
D07870
| 6件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5, PRL 💬 | 15件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
1025 | Bromure d'Ipratropium | 1件: Ipratropium Ipratropium | 1件: D02212
D02212
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 86 86 |
1026 | Bronchial mucus collection | - | - | - | - | 1件: 299 299 |
1027 | Bronchitol | 1件: Mannitol Mannitol | 1件: D00062
D00062
| - | - | 1件: 299 299 |
1028 | Broncho-Vaxom | 1件: OM85 OM85 | - | - | - | 1件: 85 85 |
1029 | Bronchoalveolar lavage (BAL fluid) | - | - | - | - | 3件: 49 49, 51, 85 |
1030 | Bronchoalveolar lavage (BAL) | - | - | - | - | 1件: 84 84 |
1031 | Bronchoalveolar lavage fluid collection | - | - | - | - | 1件: 229 229 |
1032 | Bronchodilator Response | - | - | - | - | 1件: 294 294 |
1033 | Bronchoscopy with BAL | - | - | - | - | 1件: 299 299 |
1034 | Bronchoscopy with bronchoalveolar lavage | - | - | - | - | 1件: 84 84 |
1035 | BRV 2.5 mg | - | - | - | - | 1件: 309 309 |
1036 | BRV 25 mg | - | - | - | - | 1件: 309 309 |
1037 | BRV 50 mg | - | - | - | - | 1件: 309 309 |
1038 | BRX-345 | - | - | - | - | 2件: 2 2, 15 |
1039 | Bryostatin 1 | 1件: Bryostatin 1 Bryostatin 1 | - | - | - | 1件: 62 62 |
1040 | BS01 | - | - | - | - | 1件: 90 90 |
1041 | BSF 208075 | - | - | - | - | 1件: 86 86 |
1042 | BSF 208075 or LU 208075 | - | - | - | - | 1件: 86 86 |
1043 | BT | - | - | - | - | 4件: 6 6, 96, 97, 98 |
1044 | BT-11 | - | - | - | - | 2件: 96 96, 97 |
1045 | BT-11 (1000 mg) | - | - | - | - | 1件: 97 97 |
1046 | BT-11 (500 mg) | - | - | - | - | 1件: 97 97 |
1047 | BT-11 (Omilancor) | - | - | - | - | 1件: 96 96 |
1048 | BT-11 1,000 mg | - | - | - | - | 1件: 96 96 |
1049 | BT-11 1000mg | - | - | - | - | 3件: 96 96, 97, 98 |
1050 | BT-11 500 mg | - | - | - | - | 2件: 96 96, 97 |
1051 | BT-11 500mg | - | - | - | - | 1件: 98 98 |
1052 | BT-11 Active | - | - | - | - | 2件: 96 96, 97 |
1053 | BT051 200 mg | - | - | - | - | 1件: 97 97 |
1054 | BT051 3200 mg | - | - | - | - | 1件: 97 97 |
1055 | BT051 800 mg | - | - | - | - | 1件: 97 97 |
1056 | BT051 up to 3200 mg | - | - | - | - | 1件: 97 97 |
1057 | BT061 | - | - | - | - | 1件: 46 46 |
1058 | BT061 (CD4 monoclonal antibody) | - | - | - | - | 1件: 46 46 |
1059 | BT063 | - | - | - | - | 1件: 49 49 |
1060 | BT090 | - | - | - | - | 1件: 65 65 |
1061 | BT524 | - | - | - | - | 1件: 65 65 |
1062 | BT595 | - | - | - | - | 2件: 63 63, 65 |
1063 | BT681 | - | - | - | - | 1件: 65 65 |
1064 | BT971 | - | - | - | - | 1件: 46 46 |
1065 | BTK Inhibitor | - | - | - | - | 3件: 46 46, 53, 160 |
1066 | BTRX-246040 | 1件: BTRX-246040 BTRX-246040 | - | - | - | 1件: 6 6 |
1067 | BTT-1023 | - | - | - | - | 1件: 46 46 |
1068 | BTT1023 | - | - | - | - | 1件: 94 94 |
1069 | BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product | - | - | - | - | 1件: 94 94 |
1070 | BTX-A | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 |
1071 | Bucelipase alfa | 1件: Bucelipase alfa Bucelipase alfa | - | - | - | 1件: 299 299 |
1072 | Bucillamine | 1件: Bucillamine Bucillamine | 1件: D01809
D01809
| - | - | 1件: 46 46 |
1073 | Buckwheat | 1件: Buckwheat Buckwheat | - | - | - | 1件: 226 226 |
1074 | Bucladesine | 1件: Bucladesine Bucladesine | 1件: D07546
D07546
| 16件: PDE10A PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B 💬 | 18件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 246 246 |
1075 | Budenofalk | - | - | - | - | 1件: 96 96 |
1076 | Budenofalk 2mg rectal foam | - | - | - | - | 1件: 97 97 |
1077 | Budenofalk 3mg | - | - | - | - | 2件: 93 93, 97 |
1078 | Budenofalk 3mg gastro-resistant capsules | - | - | - | - | 1件: 96 96 |
1079 | Budenofalk 9mg gastro-resistant granules | - | - | - | - | 1件: 96 96 |
1080 | Budenofalk rectal foam | - | - | - | - | 1件: 97 97 |
1081 | Budenofalk® suppositories | - | - | - | - | 1件: 97 97 |
1082 | Budenofalk® suppositories (BUS) | - | - | - | - | 1件: 97 97 |
1083 | Budesonid | - | - | - | - | 1件: 95 95 |
1084 | BUDESONIDE | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 9件: 66 66, 93, 94, 95, 96, 97, 98, 228, 299 |
1085 | Budesonide ( Zentacort Capsules 3mg ) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 |
1086 | Budesonide (6 mg) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1087 | Budesonide (9 mg) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1088 | Budesonide 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1089 | Budesonide 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1090 | Budesonide 0.5mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1091 | Budesonide 1 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1092 | Budesonide 1 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1093 | Budesonide 1 mg orodispersible tablets (BUL 1 mg) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1094 | Budesonide 1mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1095 | Budesonide 2 mg orodispersible tablets (BUL 2 mg) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1096 | Budesonide 6 mg prolonged-release capsule, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1097 | Budesonide 6 mg prolonged-release capsules, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1098 | Budesonide 9 mg capsules, hard (BUX-PV) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1099 | Budesonide 9 mg prolonged-release capsule, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1100 | Budesonide 9 mg prolonged-release capsules, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1101 | Budesonide [0.4mg/ml] viscous suspension | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1102 | Budesonide MMX | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1103 | Budesonide MMX 6 mg Tablet | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1104 | Budesonide MMX® | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1105 | Budesonide MMX® 6 mg | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1106 | Budesonide MMX® 9 mg | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1107 | Budesonide oral suspension | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1108 | Budesonide oral suspension [0.2 mg/ml] | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1109 | Budesonide plus Prevacid | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
1110 | Budesonide-formoterol single inhaler | 2件: Budesonide Budesonide, Formoterol | 4件: D00246
D00246
,
D01373
,
D05277
,
D07990
| 2件: ADRB2 ADRB2, NR3C1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 299 299 |
1111 | Budesonide-MMX | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1112 | Budesonide-MMX® | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1113 | Budesonide-MMX® 6 mg | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1114 | Budesonide-MMX® 9 mg | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1115 | Budesonide-MMX™ | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
1116 | Budesonide/formoterol | 2件: Budesonide Budesonide, Formoterol | 4件: D00246
D00246
,
D01373
,
D05277
,
D07990
| 2件: ADRB2 ADRB2, NR3C1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
1117 | BUET 0.5 mg | - | - | - | - | 1件: 98 98 |
1118 | BUET 1 mg | - | - | - | - | 1件: 98 98 |
1119 | BUET 1mg | - | - | - | - | 1件: 98 98 |
1120 | BUET 2mg | - | - | - | - | 1件: 98 98 |
1121 | BUL 0.5 mg | - | - | - | - | 1件: 98 98 |
1122 | BUL 1 mg | - | - | - | - | 1件: 98 98 |
1123 | BUMEKIZUMAB | - | - | - | - | 1件: 46 46 |
1124 | Bumetanide | 1件: Bumetanide Bumetanide | 1件: D00247
D00247
| 1件: SLC12A2 SLC12A2 💬 | 3件: Pancreatic secretion Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬 | 2件: 6 6, 158 |
1125 | Bumetanide white, oblong, scored tablet | 1件: Bumetanide Bumetanide | 1件: D00247
D00247
| 1件: SLC12A2 SLC12A2 💬 | 3件: Pancreatic secretion Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬 | 1件: 6 6 |
1126 | BUPI5 | - | - | - | - | 1件: 53 53 |
1127 | Bupivacaine | 1件: Bupivacaine Bupivacaine | 2件: D01450
D01450
,
D07552
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 8件: 46 46, 51, 53, 70, 96, 168, 226, 298 |
1128 | BUPIVACAINE HYDROCHLORIDE | 1件: Bupivacaine Bupivacaine | 2件: D01450
D01450
,
D07552
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 2件: 46 46, 53 |
1129 | Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) | 1件: Bupivacaine Bupivacaine | 2件: D01450
D01450
,
D07552
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 46 46 |
1130 | Bupivacaine Injection 0.5% | 1件: Bupivacaine Bupivacaine | 2件: D01450
D01450
,
D07552
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 168 168 |
1131 | Bupivacaine, triamcinolone, and heparin (BTH) | 3件: Bupivacaine Bupivacaine, Heparin, Triamcinolone | 8件: D00385
D00385
,
D00983
,
D00984
,
D00985
,
D01450
,
D06216
,
D07510
,
D07552
| 7件: NR3C1 NR3C1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 | 5件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Neuroactive ligand-receptor interaction, Taste transduction 💬 | 1件: 226 226 |
1132 | Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine | 3件: Bupivacaine Bupivacaine, Clonidine, Epinephrine | 7件: D00095
D00095
,
D00281
,
D00604
,
D00996
,
D01450
,
D02149
,
D07552
| 14件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 70 70 |
1133 | Bupivacaine/epinephrine/dexamethasone | 3件: Bupivacaine Bupivacaine, Dexamethasone, Epinephrine | 14件: D00095
D00095
,
D00292
,
D00975
,
D00996
,
D01450
,
D01510
,
D01615
,
D01632
,
D01948
,
D02149
,
D02174
,
D02591
,
D02592
,
D07552
| 15件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, NR3C1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 96 96 |
1134 | Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml | 1件: Sufentanil Sufentanil | 2件: D00845
D00845
,
D05938
| 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 |
1135 | Bupivicaine alone | - | - | - | - | 1件: 298 298 |
1136 | Bupizenge | - | - | - | - | 1件: 53 53 |
1137 | Bupleurum+Ginkgo | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 6 6 |
1138 | Buprenorphine | 1件: Buprenorphine Buprenorphine | 2件: D00836
D00836
,
D07132
| 2件: OPRK1 OPRK1, OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 3件: 46 46, 70, 298 |
1139 | Buprenorphine Transdermal Patch | 1件: Buprenorphine Buprenorphine | 2件: D00836
D00836
,
D07132
| 2件: OPRK1 OPRK1, OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 |
1140 | Bupropion | 1件: Bupropion Bupropion | 3件: D00817
D00817
,
D07591
,
D07938
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 5件: 8 8, 18, 21, 96, 171 |
1141 | Bupropion & Citalopram | 2件: Bupropion Bupropion, Citalopram | 5件: D00817
D00817
,
D00822
,
D07591
,
D07704
,
D07938
| 3件: SLC6A2 SLC6A2, SLC6A3, SLC6A4 💬 | 8件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 18 18 |
1142 | Bupropion Hydrochloride | 1件: Bupropion Bupropion | 3件: D00817
D00817
,
D07591
,
D07938
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 171 171 |
1143 | Burlulipase | 1件: Burlulipase Burlulipase | - | - | - | 1件: 299 299 |
1144 | Burosumab | 1件: Burosumab Burosumab | 1件: D10913
D10913
| 1件: FGF23 FGF23 💬 | 11件: Breast cancer Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬 | 1件: 238 238 |
1145 | BUSILVEX | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 4件: 19 19, 36, 60, 65 |
1146 | BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 2件: 19 19, 65 |
1147 | Buspirone | 1件: Buspirone Buspirone | 2件: D00702
D00702
,
D07593
| 2件: DRD2 DRD2, HTR1A 💬 | 10件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway 💬 | 3件: 6 6, 51, 179 |
1148 | Buspirone Hydrochloride | 1件: Buspirone Buspirone | 2件: D00702
D00702
,
D07593
| 2件: DRD2 DRD2, HTR1A 💬 | 10件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 |
1149 | Busulfan | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 13件: 19 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 |
1150 | Busulfan IV | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 1件: 65 65 |
1151 | Busulfan test dose | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 1件: 65 65 |
1152 | Busulfan, Cyclophosphamide, Antithymocyte Globulin | 2件: Busulfan Busulfan, Cyclophosphamide | 3件: D00248
D00248
,
D00287
,
D07760
| - | - | 2件: 19 19, 20 |
1153 | Busulfan, Cyclophosphamide, ATG | 2件: Busulfan Busulfan, Cyclophosphamide | 3件: D00248
D00248
,
D00287
,
D07760
| - | - | 1件: 19 19 |
1154 | Busulfan, Cyclophosphamide, ATG, GCSF | 2件: Busulfan Busulfan, Cyclophosphamide | 3件: D00248
D00248
,
D00287
,
D07760
| - | - | 2件: 65 65, 284 |
1155 | Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen) | 4件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit), Busulfan, Cyclophosphamide, Fludarabine | 5件: D00248
D00248
,
D00287
,
D01907
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 326 326 |
1156 | Busulfan, Fludarabine and ATG | 2件: Busulfan Busulfan, Fludarabine | 3件: D00248
D00248
,
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 |
1157 | Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine. | 4件: Busulfan Busulfan, Cyclophosphamide, Cyclosporine, Fludarabine | 6件: D00184
D00184
,
D00248
,
D00287
,
D01907
,
D07760
,
D07966
| 6件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2, RRM1 💬 | 38件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Glutathione metabolism, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Pyrimidine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 60 60, 285 |
1158 | Busulfan, Fludarabine, ATG, TLI | 2件: Busulfan Busulfan, Fludarabine | 3件: D00248
D00248
,
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 284 |
1159 | Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF | 6件: Busulfan Busulfan, Filgrastim, Fludarabine, Methotrexate, Phosphate ion, Tacrolimus | 8件: D00107
D00107
,
D00142
,
D00248
,
D01907
,
D02115
,
D03235
,
D07966
,
D08556
| 9件: CSF3R CSF3R, DHFR, DHFR2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2, RRM1 💬 | 47件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Antifolate resistance, Axon guidance, B cell receptor signaling pathway, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Drug metabolism - other enzymes, Folate biosynthesis, Glucagon signaling pathway, Glutamatergic synapse, Glutathione metabolism, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, One carbon pool by folate, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Pyrimidine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 |
1160 | BUSULFANO | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 1件: 19 19 |
1161 | Butanoic acid | 1件: Butyric Acid Butyric Acid | 1件: D05866
D05866
| - | - | 3件: 34 34, 51, 97 |
1162 | Butylphthalide | 1件: Butylphthalide Butylphthalide | - | - | - | 4件: 2 2, 6, 18, 22 |
1163 | Butyrate | 1件: Butyric Acid Butyric Acid | 1件: D05866
D05866
| - | - | 2件: 97 97, 291 |
1164 | Butyrate enemas + routine management | 1件: Butyric Acid Butyric Acid | 1件: D05866
D05866
| - | - | 1件: 291 291 |
1165 | BUU 0.4mg/ml | - | - | - | - | 1件: 98 98 |
1166 | BVS857 | - | - | - | - | 1件: 1 1 |
1167 | BX-1 | - | - | - | - | 1件: 13 13 |
1168 | BX004-A | - | - | - | - | 1件: 299 299 |
1169 | By demand | - | - | - | - | 2件: 96 96, 97 |
1170 | BYDUREON | 1件: Exenatide Exenatide | 1件: D04121
D04121
| 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 2件: 6 6, 17 |
1171 | Bydureon 2 mg powder and solvent for prolonged-release suspension | 2件: Exenatide Exenatide, Manganese citrate | 1件: D04121
D04121
| 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 6 6 |
1172 | Byetta | 1件: Exenatide Exenatide | 1件: D04121
D04121
| 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 3件: 6 6, 78, 193 |
1173 | Byetta 5 micrograms | 1件: Exenatide Exenatide | 1件: D04121
D04121
| 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 6 6 |
1174 | BYM338 | - | - | - | - | 1件: 15 15 |
1175 | BYM338 (Bimagrumab) | 1件: Bimagrumab Bimagrumab | 1件: D10620
D10620
| 2件: ACVR2A ACVR2A, ACVR2B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 15 15 |
1176 | BYM338/bimagrumab | 1件: Bimagrumab Bimagrumab | 1件: D10620
D10620
| 2件: ACVR2A ACVR2A, ACVR2B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 15 15 |
1177 | Béfizal | - | - | - | - | 1件: 302 302 |